<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell</journal-id><journal-id journal-id-type="iso-abbrev">Cell</journal-id><journal-title-group><journal-title>Cell</journal-title></journal-title-group><issn pub-type="ppub">0092-8674</issn><issn pub-type="epub">1097-4172</issn><publisher><publisher-name>Published by Elsevier Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32425270</article-id><article-id pub-id-type="pmc">7231725</article-id><article-id pub-id-type="pii">S0092-8674(20)30620-6</article-id><article-id pub-id-type="doi">10.1016/j.cell.2020.05.025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients&#x02019; B Cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Cao</surname><given-names>Yunlong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Su</surname><given-names>Bin</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Guo</surname><given-names>Xianghua</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Sun</surname><given-names>Wenjie</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Deng</surname><given-names>Yongqiang</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Bao</surname><given-names>Linlin</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Zhu</surname><given-names>Qinyu</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref><xref rid="fn1" ref-type="fn">10</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Zhang</surname><given-names>Xu</given-names></name><xref rid="aff7" ref-type="aff">7</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Zheng</surname><given-names>Yinghui</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Geng</surname><given-names>Chenyang</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au11"><name><surname>Chai</surname><given-names>Xiaoran</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>He</surname><given-names>Runsheng</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Li</surname><given-names>Xiaofeng</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Lv</surname><given-names>Qi</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au15"><name><surname>Zhu</surname><given-names>Hua</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au16"><name><surname>Deng</surname><given-names>Wei</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au17"><name><surname>Xu</surname><given-names>Yanfeng</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au18"><name><surname>Wang</surname><given-names>Yanjun</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au19"><name><surname>Qiao</surname><given-names>Luxin</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au20"><name><surname>Tan</surname><given-names>Yafang</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au21"><name><surname>Song</surname><given-names>Liyang</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au22"><name><surname>Wang</surname><given-names>Guopeng</given-names></name><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au23"><name><surname>Du</surname><given-names>Xiaoxia</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au24"><name><surname>Gao</surname><given-names>Ning</given-names></name><xref rid="aff6" ref-type="aff">6</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author" id="au25"><name><surname>Liu</surname><given-names>Jiangning</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author" id="au26"><name><surname>Xiao</surname><given-names>Junyu</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author" id="au27"><name><surname>Su</surname><given-names>Xiao-dong</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff5" ref-type="aff">5</xref></contrib><contrib contrib-type="author" id="au28"><name><surname>Du</surname><given-names>Zongmin</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="au29"><name><surname>Feng</surname><given-names>Yingmei</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author" id="au30"><name><surname>Qin</surname><given-names>Chuan</given-names></name><xref rid="aff4" ref-type="aff">4</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au31"><name><surname>Qin</surname><given-names>Chengfeng</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au32"><name><surname>Jin</surname><given-names>Ronghua</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor3" ref-type="corresp">&#x02217;&#x02217;&#x02217;</xref></contrib><contrib contrib-type="author" id="au33"><name><surname>Xie</surname><given-names>X. Sunney</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff6" ref-type="aff">6</xref><xref rid="aff9" ref-type="aff">9</xref><xref rid="fn2" ref-type="fn">11</xref><xref rid="cor4" ref-type="corresp">&#x02217;&#x02217;&#x02217;&#x02217;</xref></contrib><aff id="aff1"><label>1</label>Beijing Advanced Innovation Center for Genomics (ICG) &#x00026; Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing 100871, China</aff><aff id="aff2"><label>2</label>Beijing Youan Hospital, Capital Medical University, Beijing 100069, China</aff><aff id="aff3"><label>3</label>State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China</aff><aff id="aff4"><label>4</label>Key Laboratory of Human Disease Comparative Medicine, Chinese Ministry of Health, Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing, China</aff><aff id="aff5"><label>5</label>State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking University, Beijing, China</aff><aff id="aff6"><label>6</label>Peking-Tsinghua Center for Life Sciences (CLS), Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China</aff><aff id="aff7"><label>7</label>Singlomics (Beijing DanXu Pharmaceuticals), Beijing 102206, China</aff><aff id="aff8"><label>8</label>State Key Laboratory of Membrane Biology, School of Life Sciences, Peking University, Beijing, China</aff><aff id="aff9"><label>9</label>School of Life Sciences, Peking University, Beijing 100871, China</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author</corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author</corresp><corresp id="cor3"><label>&#x02217;&#x02217;&#x02217;</label>Corresponding author</corresp><corresp id="cor4"><label>&#x02217;&#x02217;&#x02217;&#x02217;</label>Corresponding author</corresp><fn id="fn1"><label>10</label><p id="ntpara0010">These authors contributed equally</p></fn><fn id="fn2"><label>11</label><p id="ntpara0015">Lead Contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>18</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>9</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>5</month><year>2020</year></pub-date><volume>182</volume><issue>1</issue><fpage>73</fpage><lpage>84.e16</lpage><history><date date-type="received"><day>24</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>7</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>13</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 Published by Elsevier Inc.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder/><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here, we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput single-cell RNA and VDJ sequencing of antigen-enriched B cells from 60 convalescent patients. From 8,558 antigen-binding IgG1<sup>+</sup> clonotypes, 14 potent neutralizing antibodies were identified, with the most potent one, BD-368-2, exhibiting an IC<sub>50</sub> of 1.2 and 15&#x000a0;ng/mL against pseudotyped and authentic SARS-CoV-2, respectively. BD-368-2 also displayed strong therapeutic and prophylactic efficacy in SARS-CoV-2-infected hACE2-transgenic mice. Additionally, the 3.8&#x000a0;&#x000c5; cryo-EM structure of a neutralizing antibody in complex with the spike-ectodomain trimer revealed the antibody&#x02019;s epitope overlaps with the ACE2 binding site. Moreover, we demonstrated that SARS-CoV-2-neutralizing antibodies could be directly selected based on similarities of their predicted CDR3<sub>H</sub> structures to those of SARS-CoV-neutralizing antibodies. Altogether, we showed that human neutralizing antibodies could be efficiently discovered by high-throughput single B cell sequencing in response to pandemic infectious diseases.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1_lrg"/></fig></abstract><abstract abstract-type="teaser" id="abs0025"><p>Neutralizing antibodies, which could effectively block virus entry into host cells, are urgently needed for intervention against COVID-19. Using high-throughput single-cell RNA sequencing, Cao et&#x000a0;al. identified fourteen potent neutralizing antibodies from 60 convalescent patients&#x02019; B cells. The most potent antibody, BD-368-2, exhibits high therapeutic and prophylactic efficacy in SARS-CoV-2-infected mice.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>single-cell sequencing</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>neutralizing antibody</kwd><kwd>convalescent patient</kwd><kwd>B cell</kwd><kwd>CDR3</kwd></kwd-group></article-meta><notes><p id="misc0010">Published: May 18, 2020</p></notes></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">Coronavirus disease 2019 (COVID-19) caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as a severe pandemic (<xref rid="bib5" ref-type="bibr">Callaway et&#x000a0;al., 2020</xref>). Both SARS-CoV-2 and SARS-CoV belong to lineage B of the betacoronavirus genus (<xref rid="bib66" ref-type="bibr">Zhou et&#x000a0;al., 2020</xref>, <xref rid="bib58" ref-type="bibr">Wu et&#x000a0;al., 2020</xref>), and their RNA genomes share around 82% identity (<xref rid="bib8" ref-type="bibr">Chan et&#x000a0;al., 2020</xref>). The mechanisms by which SARS-CoV-2 infects target cells have been well studied and recently reported (<xref rid="bib21" ref-type="bibr">Hoffmann et&#x000a0;al., 2020</xref>, <xref rid="bib52" ref-type="bibr">Walls et&#x000a0;al., 2020</xref>). Similar to SARS-CoV, the spike (S) glycoprotein on the surface of SARS-CoV-2 mediates membrane fusion and receptor recognition of the virus (<xref rid="bib57" ref-type="bibr">Wrapp et&#x000a0;al., 2020</xref>). The S1 subunit at the N-terminal region is responsible for virus attachment and contains the receptor-binding domain (RBD), which directly binds to the ACE2 receptor on the host cell. Currently, no validated therapeutics against virus-target interactions are available for COVID-19.</p><p id="p0035">Convalescent patients&#x02019; plasma, which contains neutralizing antibodies produced by the adaptive immune response, has led to a clear clinical improvement of both mild and severe COVID-19 patients when used as a therapeutic modality (<xref rid="bib9" ref-type="bibr">Chen et&#x000a0;al., 2020</xref>, <xref rid="bib48" ref-type="bibr">Shen et&#x000a0;al., 2020</xref>, <xref rid="bib6" ref-type="bibr">Cao, 2020</xref>). However, therapeutic use is limited since plasma cannot be produced on a large scale. On the other hand, neutralizing monoclonal antibodies (mAbs) isolated from convalescent patient&#x02019;s memory B cells may serve as a promising intervention to SARS-CoV-2 due to their scalability and therapeutic effectiveness. Human-sourced mAbs targeting viral surface proteins have increasingly shown their therapeutic and prophylactic efficacy against infectious diseases such as HIV, Ebola, and Middle Eastern respiratory syndrome (MERS) (<xref rid="bib12" ref-type="bibr">Corti et&#x000a0;al., 2016</xref>, <xref rid="bib53" ref-type="bibr">Wang et&#x000a0;al., 2018</xref>, <xref rid="bib44" ref-type="bibr">Scheid et&#x000a0;al., 2009</xref>). Their safety and potency in patients have been demonstrated in multiple clinical trials (<xref rid="bib59" ref-type="bibr">Xu et&#x000a0;al., 2019</xref>, <xref rid="bib7" ref-type="bibr">Caskey et&#x000a0;al., 2017</xref>). Despite their advantages, screening for potent neutralizing mAbs from human memory B cells is often a slow and laborious process, which is not ideal when responding to a worldwide health emergency. A rapid and efficient method for screening SARS-CoV-2-neutralizing mAbs is urgently needed.</p><p id="p0040">Due to VDJ recombination and somatic hypermutation, B cells exhibit diverse B cell repertoires, necessitating the analysis of one B cell at a time (<xref rid="bib3" ref-type="bibr">Bassing et&#x000a0;al., 2002</xref>). Techniques, such as single-cell clonal amplification of memory B cells, are usually utilized to obtain paired immunoglobulin heavy-light chain RNA sequences from the heterogeneous B cell population to produce mAbs (<xref rid="bib17" ref-type="bibr">El Debs et&#x000a0;al., 2012</xref>, <xref rid="bib41" ref-type="bibr">Niu et&#x000a0;al., 2019</xref>). Clonal amplification of Epstein-Barr virus (EBV)-immortalized memory B cells from convalescent patients has proved successful in isolating neutralizing mAbs against viral infections such as HIV, Dengue, and MERS (<xref rid="bib4" ref-type="bibr">Burton et&#x000a0;al., 2009</xref>, <xref rid="bib11" ref-type="bibr">Corti et&#x000a0;al., 2015</xref>, <xref rid="bib44" ref-type="bibr">Scheid et&#x000a0;al., 2009</xref>, <xref rid="bib47" ref-type="bibr">Setthapramote et&#x000a0;al., 2012</xref>). Yet, due to the time-consuming incubation and screening steps, the technique takes several months at least to complete a successful screen.</p><p id="p0045">On the other hand, single-cell RT-PCR combined with fluorescence-activated cell sorting (FACS) or optofluidics platform, such as Beacon (Berkley Light), could obtain antibody sequences in several days by performing nested PCR on single antigen-binding memory B cells after single-cell sorting (<xref rid="bib50" ref-type="bibr">Tiller et&#x000a0;al., 2008</xref>, <xref rid="bib55" ref-type="bibr">Wardemann et&#x000a0;al., 2003</xref>, <xref rid="bib69" ref-type="bibr">Wrammert et al., 2008</xref>, <xref rid="bib30" ref-type="bibr">Liao et&#x000a0;al., 2009</xref>). The method has led to efficient isolation of neutralizing mAbs in various infectious diseases, including HIV and MERS (<xref rid="bib44" ref-type="bibr">Scheid et&#x000a0;al., 2009</xref>, <xref rid="bib53" ref-type="bibr">Wang et&#x000a0;al., 2018</xref>). Nevertheless, the recent development of high-throughput single-cell RNA and VDJ sequencing of B cell receptor repertoires using 10X Chromium has outperformed single-cell RT-PCR in terms of B cell screening throughput (<xref rid="bib19" ref-type="bibr">Goldstein et&#x000a0;al., 2019</xref>, <xref rid="bib22" ref-type="bibr">Horns et&#x000a0;al., 2020</xref>). The microfluidic-based technique could obtain auto-paired heavy- and light-chain sequences from tens of thousands single B cells in one run and has successfully been used for the isolation of human neutralizing mAbs against HIV (<xref rid="bib70" ref-type="bibr">Setliff et al., 2019</xref>).</p><p id="p0050">Here, we report the rapid and efficient identification of SARS-CoV-2-neutralizing antibodies achieved by high-throughput single-cell RNA and VDJ sequencing of antigen-binding B cells from convalescent COVID-19 patients. Over 8,500 antigen-binding B cell clonotypes expressing immunoglobulin G1 (IgG1) antibodies were identified from 60 convalescent patients. In total, we identified 14 potent neutralizing mAbs, among which the most potent mAb, BD-368-2, exhibited an IC<sub>50</sub> of 1.2 and 15&#x000a0;ng/mL against pseudotyped and authentic SARS-CoV-2. Additionally, <italic>in&#x000a0;vivo</italic> experiments confirmed that BD-368-2 could provide strong therapeutic efficacy and prophylactic protection against SARS-CoV-2, using the hACE2 transgenic mice model (<xref rid="bib2" ref-type="bibr">Bao et&#x000a0;al., 2020</xref>, <xref rid="bib60" ref-type="bibr">Yang et&#x000a0;al., 2007</xref>, <xref rid="bib36" ref-type="bibr">McCray et&#x000a0;al., 2007</xref>).</p><p id="p0055">Further, we solved the cryoelectron microscopy (cryo-EM) structure of one neutralizing mAb, BD-23, in complex with the SARS-CoV-2 spike ectodomain trimer and showed that its epitope overlaps with the RBD/ACE2 binding motif. Moreover, based on the high conservation between SARS-CoV-2 and SARS-CoV, we demonstrated that potent neutralizing mAbs against SARS-CoV-2 could be directly chosen from the large antigen-binding clonotype library, utilizing the CDR3<sub>H</sub> structure&#x02019;s similarity to that of SARS-CoV-neutralizing antibody m396 (<xref rid="bib71" ref-type="bibr">Prabakaran et al., 2006</xref>, <xref rid="bib67" ref-type="bibr">Zhu et&#x000a0;al., 2007</xref>). Overall, we showed that high-throughput single-cell sequencing could lead to the identification of highly potent neutralizing mAbs that have strong therapeutic and prophylactic efficacy, which could greatly assist in the intervention of prevailing and emerging infectious diseases, such as COVID-19.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>High-Throughput Sequencing of Single B Cells from Convalescent Patients</title><p id="p0060">Unlike traditional methodologies, large-scale data obtained from high-throughput scVDJ sequencing (scVDJ-seq) enabled us to examine B cell clonotype enrichment prior to <italic>in&#x000a0;vitro</italic> antibody expression (<xref rid="bib19" ref-type="bibr">Goldstein et&#x000a0;al., 2019</xref>, <xref rid="bib13" ref-type="bibr">Croote et&#x000a0;al., 2018</xref>). B cells that share an identical CDR3 region for both heavy and light chains were grouped into the same clonotypes, and their enrichment was calculated based on the number of cells observed for the clonotype. Since antigen-activated B cells would go through clonal selection and expansion from pre-existing naive and memory B cells (<xref rid="bib39" ref-type="bibr">Murugan et&#x000a0;al., 2018</xref>, <xref rid="bib45" ref-type="bibr">Seifert and K&#x000fc; ppers, 2016</xref>), we hypothesized that enriched B cell clonotypes would more likely yield high-affinity SARS-CoV-2 binding and neutralizing antibodies.</p><p id="p0065">To exploit this hypothesis, we first collected peripheral blood mononuclear cells (PBMCs) and isolated the B cells from 12 COVID-19 convalescent patients from Beijing Youan Hospital (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). We performed small conditional RNA (scRNA) and scVDJ sequencing on the freshly isolated B cells or CD27<sup>+</sup> memory B cell subsets using 10X Chromium 5&#x02032; mRNA and VDJ sequencing (<xref rid="fig1" ref-type="fig">Figures 1</xref>
A and <xref rid="figs1" ref-type="fig">S1</xref>
A). The scVDJ data indeed revealed enriched IgG1 clonotypes (<xref rid="figs1" ref-type="fig">Figures S1</xref>F and S1H), and the CD27<sup>+</sup> memory B cell selection largely improved the number of memory B cells sequenced (<xref rid="figs1" ref-type="fig">Figures S1</xref>D and S1E) as well as the IgG1 clonotypes discovered (<xref rid="figs1" ref-type="fig">Figures S1</xref>G and S1I). However, from the 130 <italic>in&#x000a0;vitro</italic>-expressed mAbs selected from memory B cells containing enriched IgG1<sup>+</sup> clonotypes (<xref rid="mmc2" ref-type="supplementary-material">Table S2</xref>), only one out of the two RBD-binding mAbs, named BD-23, showed a weak virus neutralization ability against pseudotyped and authentic SARS-CoV-2 (<xref rid="figs1" ref-type="fig">Figures S1</xref>B and S1C). The low efficiency in terms of RBD-binding mAbs and neutralizing mAbs identification necessitates an antigen-affinity based selection, which could greatly enrich for spike/RBD binding B cells.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Efficient Neutralizing Antibody Identification through Antigen-Enriched High-Throughput Single-Cell RNA Sequencing</p><p>(A) Schematic overview of the neutralizing antibody identification process. The sequence of the mAbs could be obtained within 2&#x000a0;days using 10X Genomics 5&#x02032; VDJ sequencing.</p><p>(B) Cell-type identification of the single B cells binding RBD (batch 5) based on gene expression. Only productive heavy-light chain-paired single cells are analyzed. See also <xref rid="figs1" ref-type="fig">Figures S1</xref> and <xref rid="figs2" ref-type="fig">S2</xref>.</p><p>(C) Ideal clonotype selection for <italic>in&#x000a0;vitro</italic> expression showing clonotype&#x02019;s enrichment frequency, immunoglobulin class, cell type, and variable region mutation rate (batch 5). Ideal clonotypes are on the right side of the dashed line with four potent neutralizing mAbs selected for further characterization are labeled.</p><p>(D) Ideal clonotype selection criteria.</p><p>(E) Characteristics of RBD-binding and spike-protein binding (RBD-) antibodies. Only RBD-binding antibodies showed neutralizing ability in pseudovirus neutralization assays. An antibody was determined as ELISA positive if it showed saturated absorption at 1&#x000a0;&#x003bc;g/mL antigen and 1&#x000a0;&#x003bc;g/mL antibody concentration. K<sub>D</sub> was measured by using SPR with a 1:1 binding model.</p><p>(F) Characteristics of the antibodies selected based on different antigen enrichment methods.</p><p>See also <xref rid="figs3" ref-type="fig">Figure&#x000a0;S3</xref>.</p></caption><graphic xlink:href="gr1_lrg"/></fig><fig id="figs1"><label>Figure&#x000a0;S1</label><caption><p>Summary of the 10X scRNA and scVDJ Sequencing of 12 Convalescent Patients&#x02019; B Cells, Related to <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref></p><p>(<bold>A</bold>) Summary of the 10X scRNA and scVDJ sequencing of 12 convalescent patients&#x02019; B cells. Patient 1-9 used a MACS-based negative selection for B cell enrichment from PBMC. Patient 10-12 used a MACS-based CD27<sup>+</sup> selection for memory B cell enrichment from PBMC. Cells are assigned to the same clonotype if they have identical heavy and light chain CDR3 DNA sequences. (<bold>B</bold>) Characteristics of the selected mAbs identified from the 12 patients. mAbs are selected from clonotypes that contain IgG1-presenting memory B cells. (<bold>C</bold>) Characteristics of the neutralizing mAb BD-23. (<bold>D</bold>) t-SNE plot of patient 4&#x02019;s scRNA-seq result. Only productive Heavy-Light chain paired cells were shown. Cells are colored based on cell types. (<bold>E</bold>) t-SNE plot of patient 11&#x02019;s scRNA-seq result. (<bold>F</bold>) Top 25 most enriched clonotypes of patient 4. The clonotype containing BD-23 is labeled. (<bold>G</bold>) Ig class distribution of patient 4&#x02019;s clonotypes. (<bold>H</bold>) Top 25 most enriched clonotypes of patient 11. (<bold>I</bold>) Ig class distribution of patient 11&#x02019;s clonotypes.</p></caption><graphic xlink:href="figs1_lrg"/></fig></p></sec><sec id="sec2.2"><title>Efficient Identification of Neutralizing mAbs by High-Throughput Sequencing of Antigen-Binding Single B Cells</title><p id="p0070">To enrich for RBD-binding B cells, we utilized both biotinylated RBD and S protein to select for antigen-binding B cells through magnetic beads separation (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). Since the selection introduces a large reduction in the number of B cells, we combined the PBMCs from different patients for sufficient 10X loading. In total, we analyzed 60 convalescent patients&#x02019; antigen-binding B cells in 6 different batches (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). Since the goal was to produce neutralizing mAbs, we filtered out all B cells that failed to have productive V-J spanning heavy-light chain pairs. A total of 8,558 distinct IgG1-presenting antigen-binding clonotypes were detected (<xref rid="tbl1" ref-type="table">Table 1</xref>
). Furthermore, the scRNA-seq data enabled us to perform cell-typing based on mRNA expression for memory B cell identifications (<xref rid="fig1" ref-type="fig">Figures 1</xref>B and <xref rid="figs2" ref-type="fig">S2</xref>
). We observed sufficient separation between naive B cells and memory B cells, as well as non-B cells versus memory B cells. However, a clear separation between switched/non-switched memory B cells and exhausted memory B cells may not be observed in some batches, mostly due to the relatively low sequencing depth and the low number of genes detected per cell of the scRNA sequencing (<xref rid="mmc3" ref-type="supplementary-material">Table S3</xref>).<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Summary of the 10X scRNA and scVDJ Sequencing of Antigen-Binding B Cells</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Enrichment Antigen</th><th>PBMC Status</th><th>VJ Paired Cells</th><th>Naive B Cells</th><th>Memory B Cells</th><th>Exhausted B Cells</th><th>Non-B Cells</th><th>IgG1 Clonotypes</th></tr></thead><tbody><tr><td>Batch 1</td><td>S protein</td><td>fresh</td><td>14,895</td><td>5,417</td><td>6,333</td><td>1,680</td><td>1,465</td><td>2,598</td></tr><tr><td>Batch 2</td><td>S protein</td><td>frozen</td><td>6,962</td><td>1,051</td><td>1,161</td><td>362</td><td>4,388</td><td>883</td></tr><tr><td>Batch 3</td><td>RBD protein</td><td>fresh</td><td>6,000</td><td>1,668</td><td>2,603</td><td>498</td><td>1,231</td><td>812</td></tr><tr><td>Batch 4</td><td>S1 (RBD-)</td><td>fresh</td><td>11,536</td><td>3,202</td><td>6,413</td><td>1,710</td><td>211</td><td>3,093</td></tr><tr><td>Batch 5</td><td>RBD protein</td><td>fresh</td><td>8,020</td><td>3,532</td><td>3,302</td><td>823</td><td>363</td><td>916</td></tr><tr><td>Batch 6</td><td>RBD protein</td><td>fresh</td><td>2,925</td><td>1,177</td><td>1,353</td><td>260</td><td>135</td><td>256</td></tr><tr><td>Total</td><td/><td/><td>50,338</td><td>16,047</td><td>21,165</td><td>5,333</td><td>7,793</td><td>8,558</td></tr></tbody></table><table-wrap-foot><fn><p>The experimental details for each sequencing batch. Enrichment antigen refers to the antigen used for the MACS pull-down. Batch 4 was performed on samples that have RBD-binding B cells filtered. PBMC status refers to whether the PBMC used were previously frozen. VJ paired cells refer to cells that both full-length heavy- and light-chain variable regions were detected. Cells are assigned to the same clonotype if they have identical heavy- and light-chain CDR3 DNA sequences. See also <xref rid="figs2" ref-type="fig">Figure&#x000a0;S2</xref>.</p></fn></table-wrap-foot></table-wrap><fig id="figs2"><label>Figure&#x000a0;S2</label><caption><p>Summary of the 10X scRNA and scVDJ Sequencing of Antigen-Binding B Cells, Related to <xref rid="tbl1" ref-type="table">Table 1</xref></p><p><bold>A) &#x02013; E)</bold> t-SNE plot of productive heavy-light chain paired single cells in each batch. Cells are colored based on cell types.</p></caption><graphic xlink:href="figs2_lrg"/></fig></p><p id="p0075">To increase the efficiency of neutralizing mAbs identification, we developed a set of criteria to filter out the clonotypes that have low chances to produce neutralizing mAbs (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D). First, only enriched clonotypes containing IgG1-expressing B cells were selected (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C and <xref rid="figs3" ref-type="fig">S3</xref>
A), since IgG1-expressing B cells respond strongly to viral stimuli (<xref rid="bib51" ref-type="bibr">Vidarsson et&#x000a0;al., 2014</xref>). Second, IgG2-expressing B cells normally respond weakly to viral pathogens, and thus IgG2-presenting clonotypes were not included as ideal candidates (<xref rid="bib24" ref-type="bibr">Irani et&#x000a0;al., 2015</xref>). Next, clonotypes that did not contain any B cells with a somatic hypermutation rate (SHM) higher than 2% indicate insufficient affinity maturation and were excluded (<xref rid="bib13" ref-type="bibr">Croote et&#x000a0;al., 2018</xref>, <xref rid="bib37" ref-type="bibr">Methot and Di Noia, 2017</xref>). Last, as exhausted B cells and naive B cells respond less effective to antigen stimuli (<xref rid="bib38" ref-type="bibr">Moir and Fauci, 2014</xref>), clonotypes that contained only exhausted memory B cells or naive B cells were not considered as ideal candidates (<xref rid="fig1" ref-type="fig">Figures 1</xref>B and <xref rid="figs2" ref-type="fig">S2</xref>). Together, a total of 169 ideal candidates were selected from enriched clonotypes and were expressed in HEK293 cells through transfection (<xref rid="mmc2" ref-type="supplementary-material">Table S2</xref>). Meanwhile, 47 non-ideal candidates were also expressed <italic>in&#x000a0;vitro</italic> as a reference to validate the effectiveness of our selection criteria (<xref rid="mmc2" ref-type="supplementary-material">Table S2</xref>).<fig id="figs3"><label>Figure&#x000a0;S3</label><caption><p>Ideal Antibody Selection from Enriched IgG1<sup>+</sup> clonotypes for <italic>In&#x000a0;Vitro</italic> Expression, Related to <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref></p><p>(<bold>A</bold>) Ideal antibody selection based on clonotype enrichment frequency, Ig class, cell type, and VDJ region mutation rate. Ideal antibodies are on the right side of the dashed line. (<bold>B</bold>) Non-ideal candidates showed less strong binding and neutralizing mAbs. (<bold>C</bold>) The comparison of the proportion of strong binding and neutralizing mAbs identified from ideal candidates and non-ideal candidates (Fisher&#x02019;s exact test, <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001). (<bold>D</bold>) The comparison of the proportion of strong binding and neutralizing mAbs identified from RBD-enriched ideal candidates and non-ideal candidates (Fisher&#x02019;s exact test, <sup>&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.01, <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001).</p></caption><graphic xlink:href="figs3_lrg"/></fig></p><p id="p0080">The purified mAbs were tested for SARS-CoV-2 RBD/spike reactivity by ELISA and surface plasmon resonance (SPR), and 149 S-binding mAbs were identified, among which over half of the mAbs bind to the RBD. We further screened all ELISA-positive mAbs for neutralizing ability using a SARS-CoV-2 pseudovirus system. We found that only RBD-binding mAbs showed pseudovirus neutralization effects (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>E), and only mAbs bound to the RBD with a K<sub>D</sub> smaller or close to the dissociation constant of ACE2/RBD (15.9&#x000a0;nM) (<xref rid="figs5" ref-type="fig">Figure&#x000a0;S5</xref>
B), would have significant neutralization effects (IC<sub>50</sub>&#x000a0;&#x0003c; 3&#x000a0;&#x003bc;g/mL) on SARS-CoV-2 pseudovirus (<xref rid="figs4" ref-type="fig">Figures S4</xref>
A and S4B). Both full-length S protein and the RBD protein could enrich for RBD-binding mAbs but with distinct efficiency (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>F). Using the RBD protein as the enrichment antigen resulted in an RBD ELISA-positive rate 3-fold higher than using S protein. Most importantly, mAbs selected from ideal candidates showed an efficiency of 46% and 25% in identifying strong RBD-binding mAbs (K<sub>D</sub>&#x000a0;&#x0003c; 20&#x000a0;nM) and SARS-CoV-2 neutralizing mAbs, respectively (<xref rid="figs3" ref-type="fig">Figure&#x000a0;S3</xref>D), which is significantly higher compared to the non-ideal mAbs candidates (<xref rid="figs3" ref-type="fig">Figures S3</xref>B and S3C).<fig id="figs5"><label>Figure&#x000a0;S5</label><caption><p>K<sub>D</sub> Measurement and ACE2/RBD Binding Inhibition for the Potent Neutralizing mAbs, Related to <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref></p><p>(<bold>A</bold>) Dissociation constant measurement of the representing mAbs against RBD. K<sub>D</sub> is calculated using a 1:1 binding model. All measurements are performed by using a serial 2-fold dilution of biotinylated RBD, starting from 50&#x000a0;nM (Yellow) to 1.56&#x000a0;nM (Black). (<bold>B</bold>) Dissociation constant measurement of ACE2 against RBD. (<bold>C</bold>) ACE2/RBD binding inhibition rate determined by ACE2 competition ELISA assay. The data were obtained from a single representative experiment with three replicates. Data are represented as mean &#x000b1; SD (<bold>D</bold>) IC<sub>50</sub> and IC<sub>80</sub> calculated from ACE2 competence ELISA assays by fitting a four-parameter logistic regression model.</p></caption><graphic xlink:href="figs5_lrg"/></fig><fig id="figs4"><label>Figure&#x000a0;S4</label><caption><p>Binding Specificity and Neutralizing Abilities of the Non-potent Neutralizing mAbs, Related to <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref></p><p>(<bold>A</bold>) Neutralization potency measured by a SARS-CoV-2 spike-pseudotyped VSV neutralization assay. Data for each mAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean &#x000b1; SD. IC<sub>50</sub> and IC<sub>80</sub> were calculated by fitting a four-parameter logistic curve. (<bold>B</bold>) Characteristics of the neutralizing mAbs. K<sub>D</sub> is measured using SPR with a 1:1 binding model targeting biotinylated RBD protein. The somatic hypermutation rate (SHM) is calculated from mutated DNA sequences of the heavy- chain variable regions (V, D, and J regions) using Igblast.</p></caption><graphic xlink:href="figs4_lrg"/></fig></p></sec><sec id="sec2.3"><title>High Neutralizing Potency against SARS-CoV-2 among mAbs from Enriched Clonotypes</title><p id="p0085">Among all the neutralizing mAbs isolated from enriched clonotypes, seven of them showed potent neutralization ability with an IC<sub>50</sub> lower than 0.05&#x000a0;&#x003bc;g/mL against SARS-CoV-2 pseudovirus (<xref rid="fig2" ref-type="fig">Figures 2</xref>A and 2C). The most potent mAb BD-368-2, which was selected from the same clonotype as BD-368 (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>C), exhibited an IC<sub>50</sub> of 1.2&#x000a0;ng/mL. All seven mAbs bind strongly to the RBD with nM or sub-nM K<sub>D</sub>, revealed by SPR (<xref rid="figs5" ref-type="fig">Figure&#x000a0;S5</xref>A), and could competitively inhibit the ACE2 binding with the RBD (<xref rid="figs5" ref-type="fig">Figure S5</xref>C and S5D). To evaluate their neutralization potential against the authentic virus, we performed the plaque reduction neutralization test (PRNT) using authentic SARS-CoV-2 isolated from COVID-19 patients. Among all mAbs tested, BD-368-2 displayed the highest potency against the authentic virus with an IC<sub>50</sub> of 15&#x000a0;ng/mL (<xref rid="fig2" ref-type="fig">Figures 2</xref>B and 2C). To further validate the authentic virus neutralization shown by PRNT, we performed the cytopathic effect (CPE) inhibition assay using BD-218 on authentic SARS-CoV-2. BD-218 showed complete viral inhibition across all three replicates, at the concentration of 1.2&#x000a0;&#x003bc;g/mL (<xref rid="figs6" ref-type="fig">Figures S6</xref>
A and S6B), consistent with the PRNT results. Together, our data have shown that highly potent neutralizing mAbs could be identified from convalescent patients by high-throughput single-cell sequencing of antigen-binding B cells.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Affinity Specificity and Neutralizing Abilities of the Potent Neutralizing mAbs</p><p>(A) Neutralization potency measured by using a pseudotyped virus neutralization assay. Data for each mAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean &#x000b1; SD. See also <xref rid="figs4" ref-type="fig">Figure&#x000a0;S4</xref>.</p><p>(B) Neutralization potency measured by an authentic SARS-CoV-2 plaque reduction neutralizing test (PRNT) assay. Data for each mAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean &#x000b1; SD. See also <xref rid="figs6" ref-type="fig">Figure&#x000a0;S6</xref>.</p><p>(C) Characteristics of the neutralizing mAbs. IC<sub>50</sub> and IC<sub>80</sub> were calculated by using a four-parameter logistic curve fitting. K<sub>D</sub> targeting RBD was measured by using SPR with a 1:1 binding model. The somatic hypermutation rate (SHM) was calculated by comparing DNA sequences of the heavy-chain variable regions (V, D, and J regions) to germline sequences using Igblast.</p><p>See also <xref rid="figs5" ref-type="fig">Figure&#x000a0;S5</xref>.</p></caption><graphic xlink:href="gr2_lrg"/></fig><fig id="figs6"><label>Figure&#x000a0;S6</label><caption><p>Authentic SARS-CoV-2 Neutralization Potency Measured by Cytopathic Effect (CPE) Assay Showed High Consistency with PRNT, Related to <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref></p><p>(<bold>A</bold>) A serial dilution of each mAbs is tested against the authentic SARS-CoV-2 on Vero-E6 cells examined by CPE (<bold>B</bold>) Phase-contract image of Vero-E6 cells examining CPE. BD-218 shows no CPE at 1.2&#x000a0;&#x003bc;g/mL, which is consistent with the PRNT results of BD-218.</p></caption><graphic xlink:href="figs6_lrg"/></fig></p></sec><sec id="sec2.4"><title>BD-368-2 Showed High Therapeutic and Prophylactic Efficacy in hACE2 Mice</title><p id="p0090">To evaluate whether the identified neutralizing mAbs could serve as therapeutic interventions and prophylactic protection against SARS-COV-2 <italic>in&#x000a0;vivo</italic>, we tested the neutralization efficacy of BD-368-2 on hACE2 transgenic mice infected with SARS-CoV-2 (<xref rid="bib2" ref-type="bibr">Bao et&#x000a0;al., 2020</xref>). BD-368-2 was chosen since it exhibits the highest potency against both pseudotyped and authentic SARS-CoV-2. A total of 9 hACE2 transgenic mice were used in this study and were equally split into three groups (n&#x000a0;= 3). The prophylactic efficacy was examined by intraperitoneally injecting 20&#x000a0;mg/kg (of mice body weight) BD-368-2 into hACE2 transgenic mice 24&#x000a0;h before viral infection (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>
A). For the therapeutic group, 20&#x000a0;mg/kg BD-368-2 was injected 2&#x000a0;h after infection. As a negative control, 20&#x000a0;mg/kg HG1K, an IgG1 antibody against the H7N9 virus, was injected 2&#x000a0;h after infection. We recorded the body weight for each mice daily after infection for 5&#x000a0;days (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>A) and found that the therapeutic and prophylactic treatment groups maintained their body weight, whereas the negative control group significantly lost weight (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>B). This indicates that BD-368-2 applied both before and after the infection could greatly improve the physiological condition of the SARS-CoV-2-infected mice. Moreover, we analyzed the viral load by qRT-PCR of the lungs at 5 dpi (<xref rid="bib60" ref-type="bibr">Yang et&#x000a0;al.,2007</xref>) and found that injections of BD-368-2 before the viral challenge could completely inhibit SARS-CoV-2 (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C). Furthermore, applying BD-368-2 2&#x000a0;h after infection could result in a 3&#x02013;4 log decrease in virus copies in mice lung, indicating an effective reduction of SARS-CoV-2 replication (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>C). Together, BD-368-2 exhibits high therapeutic and prophylactic efficacy <italic>in&#x000a0;vivo</italic>.<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>BD-368-2 Showed High Therapeutic and Prophylactic Efficacy in SARS-CoV-2-Infected hACE2 Transgenic Mice</p><p>(A) Experimental design for therapeutic and prophylactic testing of BD-368-2 in hACE2 transgenic mice. BD-368-2 or unrelated antibody HG1K (20&#x000a0;mg/kg of body weight) was intraperitoneally injected into the transgenic mice before or after SAR-CoV-2 infection.</p><p>(B) Body-weight change (%) of the hACE2 transgenic mice recorded over 5&#x000a0;days (one-sided permutation test, <sup>&#x02217;</sup>p&#x000a0;&#x0003c; 0.05). Each group contains 3 mice. Data are represented as mean &#x000b1; SD.</p><p>(C) Virus titers of lung tissue at 5 dpi. The viral loads of the lung were determined by qRT-PCR (one-tailed t test, <sup>&#x02217;&#x02217;&#x02217;</sup>p&#x000a0;&#x0003c; 0.001). Data are represented as mean &#x000b1; SD.</p></caption><graphic xlink:href="gr3_lrg"/></fig></p></sec><sec id="sec2.5"><title>Cryo-EM Structure of the Neutralizing mAb Bound to the Trimeric Spike Protein</title><p id="p0095">Neutralizing mAbs against SARS-CoV-2 were identified efficiently after analyzing enriched clonotypes. However, due to the shallow sampling of B cells for each patient, the majority of the clonotypes did not show any enrichment. Nevertheless, the non-enriched antigen-binding clonotypes still remain as a valuable library for future identification of neutralizing mAbs. A new antibody selection criterion for non-enriched clonotypes is needed, since arbitrary selection may lead to a high percentage of weak antigen-binding mAbs and is also prone to non-specific binding during the antigen pull-down. Previously, people have used antibody structure prediction to annotate Ig-seq data for better mAbs selection (<xref rid="bib14" ref-type="bibr">DeKosky et&#x000a0;al., 2016</xref>). By selecting the mAbs that share similar CDR3<sub>H</sub> structures with reference neutralizing mAbs, the structural annotation approach has proved to be successful in improving the performance of Ig-seq as well as <italic>in&#x000a0;vitro</italic> antibody maturation (<xref rid="bib26" ref-type="bibr">Kovaltsuk et&#x000a0;al., 2017</xref>, <xref rid="bib28" ref-type="bibr">Krawczyk et&#x000a0;al., 2014</xref>, <xref rid="bib46" ref-type="bibr">Sela-Culang et&#x000a0;al., 2014</xref>). Inspired by these results, we hypothesized that CDR3<sub>H</sub>-based structure prediction could also help to annotate the scVDJ-seq data from convalescent patients, which may serve to improve the efficiency in identifying neutralizing mAbs against SARS-CoV-2.</p><p id="p0100">The main difficulty, however, lies in the selection of the reference antibody structure. To date, no SARS-CoV-2 neutralizing mAb structures are recorded in the Protein Database (PDB), which could serve as a reference. To address this, we solved the cryo-EM structure of BD23-Fab in complex with the S ectodomain trimer at an overall resolution of 3.8&#x000a0;&#x000c5; (<xref rid="fig4" ref-type="fig">Figures 4</xref>
A and <xref rid="figs7" ref-type="fig">S7</xref>
; <xref rid="mmc3" ref-type="supplementary-material">Table S4</xref>). The S ectodomain here adopts an asymmetric conformation as previously reported (<xref rid="bib57" ref-type="bibr">Wrapp et&#x000a0;al., 2020</xref>), with the RBD in one protomer (mol A) adopting an &#x0201c;up&#x0201d; position, whereas the other two RBDs (mol B and C) adopt &#x0201c;down&#x0201d; positions. In this 3D reconstruction, a single BD23-Fab is observed per S trimer, and it binds the &#x0201c;down&#x0201d; RBD in protomer B. Only the heavy chain variable domain of BD-23 is involved in binding to the RBD (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>B). Interestingly, the binding is also facilitated by an N-linked glycan on Asn165 of protomer C. Although the current resolution does not support further analysis of the molecular interactions between BD23-Fab and RBD, it is evident that BD23&#x02019;s epitope overlaps with the motif recognized by ACE2. In fact, a comparison with the RBD-ACE2 complex structure demonstrates that BD23-Fab competes with ACE2 for binding to RBD (<xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>C). This observation suggests that the SARS-CoV-2 neutralization ability of BD-23 comes from the disruption of the ACE2-RBD binding, which is highly similar to previously identified neutralizing mAbs against SARS-CoV (<xref rid="bib71" ref-type="bibr">Prabakaran et al., 2006</xref>, <xref rid="bib62" ref-type="bibr">Yuan et&#x000a0;al., 2020</xref>). Indeed, several studies have suggested that SARS-CoV-neutralizing mAbs could cross-neutralize SARS-CoV-2 (<xref rid="bib54" ref-type="bibr">Wang et&#x000a0;al., 2020</xref>, <xref rid="bib49" ref-type="bibr">Tian et&#x000a0;al., 2020</xref>, <xref rid="bib32" ref-type="bibr">Lv et&#x000a0;al., 2020</xref>), which further highlights the resemblance between the RBDs of SARS-CoV and SARS-CoV-2. Altogether, the structural observations and the high conservation between SARS-CoV and SARS-COV-2 suggest that it may also be feasible to use SARS-CoV-neutralizing mAbs&#x02019; crystal structures as a reference, to screen for SARS-CoV-2 antigen-binding clonotypes that share similar CDR3<sub>H</sub> structures to identify neutralizing mAbs.<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Cryo-EM Structure of BD23-Fab in Complex with the Spike Trimer</p><p>(A) Cryo-EM structure of the S trimer in complex with BD23-Fab reconstructed at 3.8&#x000a0;&#x000c5; resolution. The three protomers in the S trimer are depicted in cyan, green, and yellow, respectively. BD23-Fab is depicted in magenta (heavy chain) and blue (light chain).</p><p>(B) N165 glycan in the NTD of protomer C facilitates the interaction between BD23-Fab and the RBD of protomer B.</p><p>(C) The crystal structure of the RBD/ACE2 complex is overlaid onto the RBD/BD23-Fab structure. BD23-Fab would collide with ACE2 and therefore block the interaction between RBD and ACE2. RBD is shown in green and white, whereas ACE2 in orange.</p><p>See also <xref rid="figs7" ref-type="fig">Figure&#x000a0;S7</xref>.</p></caption><graphic xlink:href="gr4_lrg"/></fig><fig id="figs7"><label>Figure&#x000a0;S7</label><caption><p>Workflow for BD-23 Cryo-EM 3D Reconstructions, Related to <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref></p><p>A) A representative raw image collected using a Titan Krios 300 kV microscope with a K2 detector. B) Representative 2D classes. C) Flow chart of image processing. D) Gold standard Fourier shell correlation (FSC) curve with estimated resolution. E) Local resolution estimation of the EM map analyzed by ResMap.</p></caption><graphic xlink:href="figs7_lrg"/></fig></p></sec><sec id="sec2.6"><title>Selecting Potent Neutralizing mAbs Based on the Structural Similarity of CDR3<sub>H</sub></title><p id="p0105">We compared every IgG1-presenting clonotype&#x02019;s predicted structure based on CDR3<sub>H</sub> using FREAD to the available SARS-CoV-neutralizing mAbs&#x02019; crystal structure in the PDB database as well as the structure of BD-23. Unfortunately, no IgG1-presenting clonotypes showed high CDR3<sub>H</sub> structural similarity with BD-23. However, a total of 12 IgG1 clonotypes showed high structure similarity with PDB ID 2dd8 and 2ghw (<xref rid="mmc2" ref-type="supplementary-material">Table S2</xref>; <xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C), which corresponds to previously isolated SARS-CoV-neutralizing mAbs m396 and 80R, respectively (<xref rid="bib71" ref-type="bibr">Prabakaran et al., 2006</xref>, <xref rid="bib23" ref-type="bibr">Hwang et&#x000a0;al., 2006</xref>). The CDR3<sub>H</sub> sequence of the identified mAbs shared high homology with m396 (2dd8) (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A), which neutralizes SARS-CoV by disrupting ACE2/RBD binding (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D).<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Characteristics of the Neutralizing mAbs Identified Based on CDR3<sub>H</sub> Structural Similarity to SARS-CoV-Neutralizing mAbs</p><p>(A) The CDR3 sequence comparison between SARS-CoV-neutralizing mAb m396 and the SARS-CoV-2-neutralizing mAbs identified based on CDR3<sub>H</sub> structure similarity.</p><p>(B) Neutralization potency measured by using a pseudotyped virus neutralization assay. Data for each mAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean &#x000b1; SD.</p><p>(C) Characteristics of the neutralizing mAbs identified based on structure similarity. IC<sub>50</sub> and IC<sub>80</sub> were calculated by using a four-parameter logistic curve-fitting. K<sub>D</sub> targeting RBD was measured by using SPR with a 1:1 binding model. VDJ alignment is determined by Igblast. The CDR3<sub>H</sub> structure prediction was performed using FREAD.</p><p>(D) The crystal structure of m396-Fab/SARS-CoV-RBD. The regions corresponding to the RBD, m396-H, and m396-L domain are shown in purple, green, and orange, respectively. The structure is from PDB ID 2dd8.</p><p>(E) Authentic SARS-CoV-2 plaque reduction neutralizing test (PRNT) assay on the three selected mAbs, BD-503, BD-508, and BD-515. Data for each mAb were obtained from a representative neutralization experiment, which contains three replicates. Data are represented as mean &#x000b1; SD.</p><p>(F) Neutralization potency on authentic SARS-CoV-2 of the three selected mAbs. IC<sub>50</sub> and IC<sub>80</sub> were calculated by fitting a four-parameter logistic curve.</p></caption><graphic xlink:href="gr5_lrg"/></fig></p><p id="p0110">Surprisingly, we found that 7 out of the 12 mAbs exhibited a strong RBD-binding affinity and a potent neutralizing ability against pseudotyped SARS-CoV-2 (<xref rid="fig5" ref-type="fig">Figures 5</xref>B and 5C). The neutralization abilities of three representative mAbs, BD-503, BD-508, and BD-515, were also verified in the PRNT against authentic SARS-CoV-2 and showed high potencies (<xref rid="fig5" ref-type="fig">Figures 5</xref>E and 5F). Moreover, these mAbs were mostly encoded by VH3-66/JH6 or VH3-53/JH6 gene segments for the heavy chain and VLK1-9 or VLK1D-33/39 for the light chain (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C). Due to the similarity of amino acid sequences and VDJ combinations, we questioned whether these mAbs came from the same lineage. After RNA mutation analysis, we found that none of the mAbs was from the same lineage nor the same patients. Together, these observations suggest that stereotypic B cell receptors that bind to a particular SARS-CoV-2 epitope may exist in different individuals, similar to what has been observed in HIV, influenza, and hepatitis C (<xref rid="bib20" ref-type="bibr">Gorny et&#x000a0;al., 2009</xref>, <xref rid="bib16" ref-type="bibr">Ekiert et&#x000a0;al., 2009</xref>, <xref rid="bib33" ref-type="bibr">Marasca et&#x000a0;al., 2001</xref>). Indeed, epitope binning experiments using a double-antibodies sandwich ELISA has shown that BD-503, BD-508, and BD-515 likely share an overlapping epitope (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>
). However, more structural analysis is needed to obtain the exact epitopes to confirm whether they are largely conserved.<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Epitope Binning of the Potent Neutralizing mAbs Using Competitive ELISA</p><p>Competition tolerance was shown for each pair of neutralizing mAbs measured by double-antibody sandwich ELISA (RBD). The column indicates the primary antibody, and the row indicates the secondary antibody. Competition tolerance larger than 50% indicates a high possibility of no overlapping epitope.</p></caption><graphic xlink:href="gr6_lrg"/></fig></p></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0115">To improve the efficiency of discovering new neutralizing mAbs, we applied a systematic analysis of antibody-presenting B cells before performing <italic>in&#x000a0;vitro</italic> expression. Large-scale, single-cell resolution data obtained from scRNA and scVDJ sequencing provided the chance to perform lineage analysis, which cannot easily be accomplished using hybridoma and single-cell RT-PCR-based techniques. The ability to calculate the enrichment frequency for each clonotype not only enables priority selection of natural clonally expanded B cell lineages but also reduces the false-positive rates of non-specific antigen-binding during the antigen-enrichment step (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>A). The simultaneous measurement of mRNA expression at the single-cell level further enables cell typing of individual B cells, which is crucial for the removal of the exhausted and naive B cell subsets. However, our current shallow scRNA sequencing barely enables the accurate separation of exhausted memory B cells from non-exhausted memory B cells. Therefore, deeper sequencing of the scRNA libraries is needed to further evaluate the effectiveness of removing exhausted memory B cells to improve the identification of neutralizing mAbs.</p><p id="p0120">Besides the clonally enriched B cell clonotypes, the vast majority of the sequenced B cells were not utilized in this study but remained as a valuable library of potential neutralizing mAbs. Nevertheless, due to the lack of enrichment, mAbs selection from the large pool of unenriched B cells continued to be a problem. We, therefore, utilized bioinformatic-based selection approaches, such as CDR3<sub>H</sub> structure prediction. mAbs that shared a highly similar CDR3<sub>H</sub> structure with SARS-CoV-neutralizing antibody m396 showed a surprisingly high percentage of high neutralization potency for SARS-CoV-2. The largely conserved combination of the VDJ gene segment and likely overlapping epitopes of those mAbs suggests the existence of stereotyped B cell receptors against SARS-CoV-2. Preliminary studies of mAbs selected based on VH3-66/JH6 or VH3-53/JH6 encoded heavy chains from different individuals indeed revealed a high proportion of SARS-CoV-2 neutralization mAbs with high potency (data not shown) and support the existence of stereotyped B cell receptors for SARS-CoV-2.</p><p id="p0125">Although 72 S1/S2 (non-RBD) binding mAbs were identified, none of them exhibited pseudovirus neutralizing ability. This was an interesting result since non-RBD binding neutralizing mAbs were observed for MERS-CoV (<xref rid="bib59" ref-type="bibr">Xu et&#x000a0;al., 2019</xref>). More antibodies from the remaining pool of antigen-binding B cell clonotypes that target different regions of the antigens would be screened for neutralization ability, to further confirm the observation. Additionally, more strains of pseudoviruses could be utilized to examine potential risks of neutralization escape after virus mutation, especially at the RBD region (<xref rid="bib53" ref-type="bibr">Wang et&#x000a0;al., 2018</xref>). A possible solution to the virus mutation could be to combine two potent mAbs targeting two different epitopes. Epitope binning results (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>) suggested that BD-368, which shares the same epitope with BD-368-2, exhibited non-overlapping epitopes with most of the potent neutralizing mAbs. An antibody cocktail combining BD-368-2 with another neutralizing mAb could greatly boost SARS-CoV-2 neutralization potency compared to any individual mAbs and could largely prevent mutation escape, since the possibility of mutations appearing on both epitopes is unlikely.</p><p id="p0130">The continual dissemination of COVID-19 as a worldwide pandemic demands effective interventions against SARS-CoV-2 infections. The potent neutralizing antibodies we identified may provide an effective therapeutic and prophylactic solution, evidenced by the results on hACE2 transgenic mice. Clinical trials using BD-368-2 are underway. The application of high-throughput single-cell sequencing methodology in this study could also be expanded to infectious diseases other than COVID-19 and serve as a technical reserve for rapid neutralizing mAbs discovery during future pandemics.</p></sec><sec id="sec5"><title>STAR&#x02605;Methods</title><sec id="sec5.1"><title>Key Resources Table</title><p id="p0140">
<table-wrap position="float" id="undtbl1"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Goat anti-human IgG (H+L)/HRP</td><td>JACKSON</td><td>Cat #109-035-088; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2337584" id="interref100">AB_2337584</ext-link></td></tr><tr><td>Anti-His/HRP</td><td>ThermoFisher</td><td>Cat # MA1-21315; RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_557403" id="interref105">AB_557403</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Bacterial and Virus Strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>SARS-COV-2 VSV pseudotyped virus</td><td>NIFDC (<xref rid="bib40" ref-type="bibr">Nie et&#x000a0;al., 2020</xref>)</td><td>N/A</td></tr><tr><td>Authentic SARS-CoV-2 virus (2019-nCoVBetaCoV/Wuhan/AMMS01/2020)</td><td>Qin&#x02019;s lab</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Biological Samples</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>PBMCs from COVID-19 convalescent patients</td><td>Youan hospital</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, Peptides, and Recombinant Proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Ficoll-Paque Plus</td><td>GE Healthcare</td><td>Cat #17144002</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>ThermoFisher</td><td>Cat #10099</td></tr><tr><td>RPMI 1640 medium</td><td>ThermoFisher</td><td>Cat #12633012</td></tr><tr><td>SARS-COV-2 spike protein, His-tag</td><td>Sino Biology</td><td>Cat # 40589-V08B1</td></tr><tr><td>SARS-COV-2 RBD protein, His-tag</td><td>Sino Biology</td><td>Cat # 40592-V08B</td></tr><tr><td>Biotinylated SARS-COV-2 spike protein</td><td>Sino Biology</td><td>Cat # 40589-V08B-B</td></tr><tr><td>Biotinylated SARS-COV-2 RBD protein</td><td>Sino Biology</td><td>Cat # 40592-V08B-B</td></tr><tr><td>0.4% (w/v) Trypan blue stain</td><td>ThermoFisher</td><td>Cat # 15250061</td></tr><tr><td>Streptavidin M-280 Dynabeads</td><td>ThermoFisher</td><td>Cat # 60210</td></tr><tr><td>1x PBS, pH 7.4</td><td>ThermoFisher</td><td>Cat # 10010031</td></tr><tr><td>EDTA 0.5M, pH8.0, RNase-free</td><td>ThermoFisher</td><td>Cat # AM9260G</td></tr><tr><td>TMB Chromogen Solution (for ELISA)</td><td>ThermoFisher</td><td>Cat # 002023</td></tr><tr><td>NaCl (5 M), RNase-free</td><td>ThermoFisher</td><td>Cat # AM9760G</td></tr><tr><td>Surfactant P20</td><td>GE Healthcare</td><td>Cat #BR100054</td></tr><tr><td>ACE2 Protein, Human, Recombinant (His Tag)</td><td>Sino Biology</td><td>Cat # 10108-H08B</td></tr><tr><td>HG1K IgG1 antibody against H7N9</td><td>Sino Biology</td><td>Cat #HG1K</td></tr><tr><td>DMEM</td><td>ThermoFisher</td><td>Cat #11965092</td></tr><tr><td>HEPES (1 M)</td><td>ThermoFisher</td><td>Cat #15630080</td></tr><tr><td>LMP agarose</td><td>Promega</td><td>Cat #V3841</td></tr><tr><td>Crystal violet</td><td>SigmaAldrich</td><td>Cat # C0775</td></tr><tr><td>Formaldehyde solution</td><td>SigmaAldrich</td><td>Cat # F8775</td></tr><tr><td>Polyethylenimine</td><td>Polysciences</td><td>Cat # 23966-2</td></tr><tr><td>Papain</td><td>Sangon Biotech</td><td>Cat # A501612-0025</td></tr><tr><td>Iodoacetamide</td><td>SigmaAldrich</td><td>Cat # I1149</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Critical Commercial Reagents</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>EasySep Human B Cell Enrichment Kit</td><td>STEMCELL</td><td>Cat #19054</td></tr><tr><td>EasySep Human Memory B Cell Isolation Kit</td><td>STEMCELL</td><td>Cat #17864</td></tr><tr><td>Chromium Single Cell 5&#x02032; Library Construction Kit</td><td>10X Genomics</td><td>Cat #1000020</td></tr><tr><td>Chromium i7 Multiplex Kit</td><td>10X Genomics</td><td>Cat #120262</td></tr><tr><td>Chromium Single Cell V(D)J Enrichment Kit, Human B Cell</td><td>10X Genomics</td><td>Cat #1000016</td></tr><tr><td>Chromium Single Cell 5&#x02032; Library &#x00026; Gel Bead Kit</td><td>10X Genomics</td><td>Cat #1000014</td></tr><tr><td>Chromium Single Cell A Chip Kit</td><td>10X Genomics</td><td>Cat #1000009</td></tr><tr><td>SA sensor chip</td><td>GE Healthcare</td><td>Cat #29104992</td></tr><tr><td>Spike Protein ELISA kit</td><td>Sino Biology</td><td>Cat #KIT40591</td></tr><tr><td>Ni Sepharose 6 Fast Flow</td><td>GE healthcare</td><td>Cat # 17531803</td></tr><tr><td>Superose 6 Increase 10/300 GL</td><td>GE healthcare</td><td>Cat # 29091596</td></tr><tr><td>RNeasy Mini Kit</td><td>QIAGEN</td><td>Cat # 74104</td></tr><tr><td>PrimerScript RT Reagent Kit</td><td>TaKaRa</td><td>Cat # RR037B</td></tr><tr><td>PowerUp SYBR Green Master Mix Kit</td><td>Applied Biosystems</td><td>Cat # A25741</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Deposited Data</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Cryo-EM structure of SARS-COV-2 spike and BD23-Fab</td><td>This paper</td><td>PDB: 7BYR</td></tr><tr><td>Electron microscopy density map of SARS-COV-2 spike and BD23-Fab</td><td>This paper</td><td>EMDB: EMD-30247</td></tr><tr><td>Antibody amino acid sequences</td><td>This paper</td><td>European Genome-Phenome Archive: EGAS00001004412</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental Models: Cell Lines</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>HEK293F cells</td><td>ThermoFisher</td><td>Cat # 11625019</td></tr><tr><td>Huh7 cells</td><td>NIFDC (<xref rid="bib40" ref-type="bibr">Nie et&#x000a0;al., 2020</xref>)</td><td>N/A</td></tr><tr><td>Vero E6 cells</td><td>Qin&#x02019;s lab</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental Models: Cell Lines</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>hACE2 transgenic mice</td><td>Qin&#x02019;s lab</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Oligonucleotides</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>5&#x02032;-TCGTTTCGGAAGAGACAGGT-3&#x02032;</td><td>Qin&#x02019;s lab</td><td>N/A</td></tr><tr><td>5&#x02032;-GCGCAGTAAGGATGGCTAGT-3&#x02032;</td><td>Qin&#x02019;s lab</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Recombinant DNA</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>SARS-CoV-2&#x000a0;S gene, residues 1-1208, pcDNA</td><td>Sino Biology</td><td>N/A</td></tr><tr><td>SARS-CoV-2&#x000a0;S gene, residues 1-1208, 2P and furin cleavage mutation, T4 fibritin trimerization motif, 8xHisTag, pcDNA</td><td>This paper</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Software and Algorithms</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>cutadapt (2.9)</td><td><xref rid="bib72" ref-type="bibr">Martin, 2011</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://cutadapt.readthedocs.io/en/stable/installation.html" id="intref0010">https://cutadapt.readthedocs.io/en/stable/installation.html</ext-link></td></tr><tr><td>CellRanger (3.1.0)</td><td>10x Genomics</td><td><ext-link ext-link-type="uri" xlink:href="https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/installation" id="intref0015">https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/installation</ext-link></td></tr><tr><td>SingleR (1.0.5)</td><td><xref rid="bib75" ref-type="bibr">Aran et al., 2019</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/SingleR.html" id="intref0020">https://bioconductor.org/packages/release/bioc/html/SingleR.html</ext-link></td></tr><tr><td>Seurat (3.1.3)</td><td><xref rid="bib76" ref-type="bibr">Satija et al., 2015</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://satijalab.org/seurat/install.html" id="intref0025">https://satijalab.org/seurat/install.html</ext-link></td></tr><tr><td>IgBlast-1.15.0</td><td>National Center for Biotechnology Information (NCBI)</td><td><ext-link ext-link-type="uri" xlink:href="http://ftp://ftp.ncbi.nih.gov/blast/executables/igblast/release/1.15.0/" id="intref0030">ftp://ftp.ncbi.nih.gov/blast/executables/igblast/release/1.15.0/</ext-link></td></tr><tr><td>igraph (1.2.5)</td><td><xref rid="bib77" ref-type="bibr">Csardi and Nepusz, 2006</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/igraph/index.html" id="intref0035">https://cran.r-project.org/web/packages/igraph/index.html</ext-link></td></tr><tr><td>SAAB+</td><td><xref rid="bib27" ref-type="bibr">Kovaltsuk et&#x000a0;al., 2020</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://github.com/oxpig/saab_plus" id="intref0040">https://github.com/oxpig/saab_plus</ext-link></td></tr><tr><td>SerialEM software</td><td><xref rid="bib34" ref-type="bibr">Mastronarde, 2005</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://bio3d.colorado.edu/SerialEM" id="intref0045">https://bio3d.colorado.edu/SerialEM</ext-link></td></tr><tr><td>MotionCor2</td><td><xref rid="bib65" ref-type="bibr">Zheng et&#x000a0;al., 2017</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://emcore.ucsf.edu/ucsf-motioncor2" id="intref0050">https://emcore.ucsf.edu/ucsf-motioncor2</ext-link></td></tr><tr><td>Gctf program (v1.06)</td><td><xref rid="bib63" ref-type="bibr">Zhang, 2016</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf" id="intref0055">https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf</ext-link></td></tr><tr><td>RELION (v3.07)</td><td><xref rid="bib68" ref-type="bibr">Zivanov et&#x000a0;al., 2018</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/relion" id="intref0060">https://www2.mrc-lmb.cam.ac.uk/relion</ext-link></td></tr><tr><td>ResMap</td><td><xref rid="bib78" ref-type="bibr">Kucukelbir et al., 2014</xref></td><td><ext-link ext-link-type="uri" xlink:href="http://resmap.sourceforge.net" id="intref0065">http://resmap.sourceforge.net</ext-link></td></tr><tr><td>UCSF Chimera</td><td><xref rid="bib42" ref-type="bibr">Pettersen et&#x000a0;al., 2004</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.cgl.ucsf.edu/chimera" id="intref0070">https://www.cgl.ucsf.edu/chimera</ext-link></td></tr><tr><td>PHENIX</td><td><xref rid="bib79" ref-type="bibr">Adams et al., 2010</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www.phenix-online.org" id="intref0075">https://www.phenix-online.org</ext-link></td></tr><tr><td>Coot</td><td><xref rid="bib80" ref-type="bibr">Emsley et al., 2010</xref></td><td><ext-link ext-link-type="uri" xlink:href="https://www2.mrc-lmb.cam.ac.uk/Personal/pemsley/coot" id="intref0080">https://www2.mrc-lmb.cam.ac.uk/Personal/pemsley/coot</ext-link></td></tr><tr><td>Pymol</td><td>Schr&#x000f6;dinger</td><td><ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/" id="intref0085">https://pymol.org/2/</ext-link></td></tr></tbody></table></table-wrap>
</p></sec><sec id="sec5.2"><title>Resource Availability</title><sec id="sec5.2.1"><title>Lead Contact</title><p id="p0145">Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, X. Sunney Xie (<ext-link ext-link-type="uri" xlink:href="mailto:sunneyxie@biopic.pku.edu.cn" id="intref0090">sunneyxie@biopic.pku.edu.cn</ext-link>)</p></sec><sec id="sec5.2.2"><title>Materials Availability</title><p id="p0150">There are restrictions on the availability of antibodies due to limited stock and continued consumption. We are glad to share remaining antibodies with reasonable compensation for processing and shipping upon completion of a Material/Data Transfer Agreement for non- commercial usage.</p></sec><sec sec-type="data-availability" id="sec5.2.3"><title>Data and Code Availability</title><p id="p0155">The accession number for the human antibody sequences reported in this paper is EGA: S00001004412. Material/Data Transfer Agreements, which allow the use of the antibody sequences for non-commercial purposes but not their disclosure to third parties, are needed to obtain the sequences by contacting the Data Access Committee.</p></sec></sec><sec id="sec5.3"><title>Experimental Model and Subject Details</title><sec id="sec5.3.1"><title>Convalescent patients</title><p id="p0160">A total of 64 confirmed COVID-19 patients discharged from Beijing Youan Hospital, China, from February 01 to February 28, 2020, were enrolled in this study (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). Patients 1-12 were enrolled in the prelinamery study without antigen-enrichment. Patients 13-64, as well as 8 patents from ID 1-12, enrolled in the study corresponding to sequence batch 1-6 (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). Discharged COVID-19 patients were isolated and observed continually for 28&#x000a0;days. Follow-ups and SARS-CoV-2 RNA detection were performed weekly. The throat swabs from the upper respiratory tract, and whole blood was collected from patients at various time-points after hospitalization and during followed-up. Sample collection, processing, and laboratory testing were performed as recommended by China CDC and complied with WHO guidance. All COVID-19 patients were confirmed infected according to positive respiratory RT-PCR tests. The discharge criteria were listed as follows. First, body temperature returns to normal for more than three days. Second, absence of respiratory tract symptoms. Third, two consecutively SARS-CoV-2 RT-PCR assays of sputum with a one-day sampling interval turn negative. None of the study participants was co-infected with HIV, hepatitis B virus/hepatitis C virus, or influenza viruses. All participants did not have a comorbid condition, tuberculosis, autoimmune diseases, or related drug usage. This study and all the relevant experiments were approved by the Beijing Youan Hospital Research Ethics Committee, and written informed consent was obtained from each participant in accordance with the Declaration of Helsinki. All participants provided written informed consent for the collection of information, and their clinical samples were stored and used for research. Data generated from the research were agreed to be published.</p></sec><sec id="sec5.3.2"><title>PBMCs from blood</title><p id="p0165">All human blood samples were collected for laboratory assessments according to the doctor&#x02019;s instruction from Beijing Youan Hospital, China. Peripheral blood mononuclear cells (PBMCs) were isolated immediately from fresh blood. Primary human B lymphocytes were obtained by purification of human blood CD19<sup>+</sup> B cells or memory CD19<sup>+</sup> CD27<sup>+</sup> B cells, by immunomagnetic bead isolation (Catalog #19054 and #17864, STEMCELL), after Ficoll-Hypaque sedimentation according to standard density-gradient centrifugation methods (GE Healthcare). For each sample, the cell viability exceeded 85%. Several patients&#x02019; PBMCs were stored frozen and thawed before use. Cryopreserved PBMCs were thawed in RPMI 1640 medium supplemented with 20% fetal bovine serum.</p></sec><sec id="sec5.3.3"><title>Recombinant RBD and full-length Spike protein from SARS-CoV-2</title><p id="p0170">Spike/RBD recombinant proteins were purchased from Sino Biological Inc. with &#x0003e; 95% purity. Full-length Spike/RBD protein was expressed in the Baculovirus-Insect cell system using the DNA sequence encoding the SARS-CoV-2 spike protein (S1+S2 ECD) or RBD protein. The protein is expressed with a polyhistidine tag at the C terminus and purified in sterile 20&#x000a0;mM Tris, 300&#x000a0;mM NaCl, 10% glycerol, pH 8.0.</p></sec><sec id="sec5.3.4"><title>SARS-CoV-2 pseudovirus</title><p id="p0175">The SARS-CoV-2 pseudovirus is a gift from the Division of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC). The pseudovirus was constructed as previously described using the spike genes from strain Wuhan-Hu-1 (GenBank: MN908947)(<xref rid="bib40" ref-type="bibr">Nie et&#x000a0;al., 2020</xref>). Briefly, the SARS-CoV-2 spike gene was codon-optimized and cloned into a eukaryotic expression plasmid. 293T cells were transfected by the plasmid and later infected with a VSV pseudotyped virus (G<sup>&#x02217;</sup>&#x00394;G-VSV), which substituted the VSV-G gene with luciferase expression cassettes. The culture supernatants were harvested and filtered 24&#x000a0;h post-infection. The SARS-CoV-2 pseudovirus could not be neutralized by VSV-G antibodies, and no G<sup>&#x02217;</sup>&#x00394;G-VSV was mixed with the SARS-CoV-2 pseudovirus stock (<xref rid="bib40" ref-type="bibr">Nie et&#x000a0;al., 2020</xref>).</p></sec><sec id="sec5.3.5"><title>Authentic SARS-CoV-2 virus</title><p id="p0180">The authentic SARS-CoV-2 virus (2019-nCoV BetaCoV/Wuhan/AMMS01/2020) was isolated from a COVID-19 patient from Beijing. The RNA sequence of the isolated virus was verified by Sanger sequencing. All experiments associated with the authentic virus were conducted in Biosafety Level 3 laboratory with standard operating procedures.</p></sec><sec id="sec5.3.6"><title>hACE2 transgenic mice</title><p id="p0185">Pathogen-free, male, and female human ACE2 transgenic mice (6 - 8 wo) were obtained from the Institute of Laboratory Animal Science, Peking Union Medical College, China. The hACE2 transgenic mice have been demonstrated to be a feasible model for the SARS-CoV-2 infection study (<xref rid="bib2" ref-type="bibr">Bao et&#x000a0;al., 2020</xref>). hACE2 mice were generated as previously described (<xref rid="bib60" ref-type="bibr">Yang et&#x000a0;al., 2007</xref>), by microinjecting DNA fragments of mouse ACE2 promoter driving hACE2 coding sequence into the pronuclei of ICR mice&#x02019;s fertilized ova. The zygotes were then transplanted into the oviducts of pseudopregnant mice. These mice were bred to produce offspring for the experiment.</p></sec></sec><sec id="sec5.4"><title>Method Details</title><sec id="sec5.4.1"><title>MACS enrichment of B cells from PBMC</title><p id="p0190">B cells were isolated from fresh or previously frozen PBMCs by immunomagnetic negative selection according to the manufacturer&#x02019;s protocol (EasySep Human B Cell Enrichment Kit, STEMCELL). Non-B cells are labeled with magnetic beads and separated using an EasySep magnet. Purified B cells were eluted and washed in PBS containing 2% (v/v) fetal bovine serum (FBS) and 1&#x000a0;mM EDTA. Purified B cells were counted by using 0.4% (w/v) trypan blue stain and Countess Automated Cell Counter according to the manufacturer&#x02019;s protocol (Thermofisher).</p></sec><sec id="sec5.4.2"><title>CD27<sup>+</sup> memory B cell enrichment</title><p id="p0195">CD27<sup>+</sup> memory B cells were isolated from purified B cells by immunomagnetic positive selection according to the manufacturer&#x02019;s protocol (EasySep Human Memory B Cell Isolation Kit, STEMCELL). Briefly, CD27<sup>+</sup> B cells are labeled with magnetic beads combined with CD27 antibodies and separated using an EasySep magnet. Purified CD27<sup>+</sup> B cells were eluted and washed in PBS containing 2% (v/v) fetal bovine serum (FBS) and 1&#x000a0;mM EDTA. CD27<sup>+</sup> B cells were counted by using 0.4% (w/v) trypan blue stain and Countess Automated Cell Counter according to the manufacturer&#x02019;s protocol.</p></sec><sec id="sec5.4.3"><title>Antigen-binding B cells enrichment</title><p id="p0200">Biotinylated Spike/RBD recombinant proteins were purchased from Sino Biological Inc. Fresh antigen/streptavidin M-280 Dynabeads (Thermofisher) complex was made every time before B cell enrichment. Briefly, 100&#x000a0;&#x003bc;L of M-280 beads containing 6.5&#x000a0;&#x000d7; 10<sup>7</sup> beads were vortexed for 30&#x000a0;s and brought to room temperature before use. Beads were washed with 1&#x000a0;mL 1x PBS twice on a magnetic rack, and eluted in 100&#x000a0;&#x003bc;L 1x PBS. Beads (100&#x000a0;&#x003bc;L) were mixed with 20&#x000a0;&#x003bc;g of biotinylated spike/RBD protein and incubated at room temperature for 30&#x000a0;mins. After incubation, the complex was washed three times using 500&#x000a0;&#x003bc;L 1x PBS on a magnetic rack. The washed complex was eluted in 100&#x000a0;&#x003bc;L 1x PBS and stored on ice until use.</p><p id="p0205">Before antigen-enrichment, the complex was equilibrated at room temperature. The amount of beads complex used was calculated based on a 1:1 ratio with the number of purified B cells. The spike/RBD magnetic beads complex was added directly into the B cell mixture, mixed and incubated at 4&#x000b0;C on a thermomixer for 30&#x000a0;mins. After the incubation, the mixture was put on a magnetic rack, and the supernatant was removed. The beads were washed times by mixing off the magnet four times in total. The final antigen-enrichment B cells were eluted in 1x PBS containing 2% (v/v) fetal bovine serum (FBS) and 1&#x000a0;mM EDTA. Enriched B cells were counted by using 0.4% (w/v) trypan blue stain and Countess Automated Cell Counter according to the manufacturer&#x02019;s protocol.</p></sec><sec id="sec5.4.4"><title>Single-cell 5&#x02032; mRNA and VDJ sequencing</title><p id="p0210">After CD27<sup>+</sup> memory B cell enrichment or antigen-specific enrichment, all B cells were loaded on a 10X Chromium A Chip. If the total cell number exceeded 20,000, two individual runs would be performed. Since SARS-CoV-2 may still appear in convalescent patients&#x02019; blood (<xref rid="bib1" ref-type="bibr">An et&#x000a0;al., 2020</xref>, <xref rid="bib64" ref-type="bibr">Zhang et&#x000a0;al., 2020</xref>), we performed all the experimental processes before library preparation in a P3-level laboratory. Single-cell lysis and RNA first-strand synthesis were performed using 10X Chromium Single Cell 5&#x02032; Library &#x00026; Gel Bead Kit according to the manufacturer&#x02019;s protocol. After RNA first-strand synthesis, all viruses should be denatured since all samples were heated to 85&#x000b0;C for 5&#x000a0;mins. RNA samples were wiped with 80% EtOH for three times and sealed in a plastic box for sample transportation.</p><p id="p0215">The following RNA and VDJ library preparation is performed according to the manufacturer&#x02019;s protocol (Chromium Single Cell V(D)J Reagent Kits, 10X Genomics) in a P2 laboratory. All libraries were quantified by using Qubit 3.0 (ThermoFisher), Fragment Analyzer, and qPCR. Sequencing was performed on a Hiseq 2500 platform running Rapid SBS Kit V2 2x100bp kit (Illumina), with a 26x91 pair-end reading mode. Sequencing results were obtained within two days. Average sequencing depth aimed for the mRNA library is 10,000 read pairs per cell and 5,000 read pairs per cell for the VDJ libraries (<xref rid="mmc3" ref-type="supplementary-material">Table S3</xref>).</p></sec><sec id="sec5.4.5"><title><italic>In&#x000a0;Vitro</italic> expression of mAbs</title><p id="p0220">The selected paired heavy- and light-chain&#x02019;s cDNA was codon-optimized and cloned into expression vectors containing the IgG1 constant regions of human. IgG mAbs were expressed by transfecting HEK293 cells with equal amounts of heavy- and light-chain plasmids. The mAbs were resuspended into PBS and analyzed by SDS-PAGE.</p><p id="p0225">The numbering of mAbs is based on the order of DNA synthesis submission. BD 1-175 were mAbs produced from the experiments without using antigen enrichment (<xref rid="mmc2" ref-type="supplementary-material">Table S2</xref>). BD 176 &#x02013; 425 were mAbs produced from the Batch 1-6 with antigen enrichment, and were all selected from clonotypes that have an enrichment frequency larger than 1 (<xref rid="mmc2" ref-type="supplementary-material">Table S2</xref>). BD 492 &#x02013; 515 were mAbs selected based on CDR3<sub>H</sub> structural similarity to SARS-CoV neutralizing antibodies (<xref rid="mmc2" ref-type="supplementary-material">Table S2</xref>). BD 426 &#x02013; 491, which were not shown, were attempts trying to substitute rare DNA mutations in the FR region of the verified neutralizing mAbs, aiming for higher neutralization potency. None of the mAbs showed improvements in terms of neutralization potency, and the results were not shown. Also, the antibodies in each group may have discontinuous numbering. The excluded mAbs were the antibodies selected from clonotypes that consist of only IgM- or IgG3-presenting B cells. None of mAbs showed neutralizing ability and thus were excluded from the results.</p></sec><sec id="sec5.4.6"><title>ELISA quantification</title><p id="p0230">ELISA plates were coated with SARS-CoV-2 RBD or S protein at 0.01&#x000a0;&#x003bc;g/mL and 1&#x000a0;&#x003bc;g/mL in PBS at 4&#x000b0;C overnight. After standard washing and blocking, 100&#x000a0;&#x003bc;L 1&#x000a0;&#x003bc;g/mL antibodies was added to each well. After a 2&#x000a0;h incubation at room temperature, plates were washed and incubated with 0.08&#x000a0;&#x003bc;g/mL goat anti-human IgG (H+L)/HRP (JACKSON) for 1&#x000a0;h incubation at room temperature. Chromogen solution was used as the substrate, and absorbance at 450nm was measured by a microplate reader. A mAb is defined as ELISA-positive when the OD<sub>450</sub> is saturated using 1&#x000a0;&#x003bc;g/mL RBD/S protein.</p></sec><sec id="sec5.4.7"><title>mAbs binding affinity measurement</title><p id="p0235">The dissociation coefficient is measured by using surface plasmon resonance (SPR). Biotinylated RBD/S (Sino Biological Inc.) was immobilized to a SA sensor chip (GE Healthcare) at a level of &#x0223c;100 response units (RUs) using a Biacore T200 (GE Healthcare). Running buffer is composed of PBS pH 7.4 and 0.005% (v/v) P20. Serial dilutions of purified antibody were injected, ranging in concentration from 50 to 0.78&#x000a0;nM. The resulting data were fit to a 1:1 binding model using Biacore Evaluation Software.</p></sec><sec id="sec5.4.8"><title>ACE2 competition assay</title><p id="p0240">Biotinylated RBD (0.3&#x000a0;&#x003bc;g/mL, Sino Biological Inc.) was immobilized to an ELISA plate. After standard washing, 0.05&#x000a0;&#x003bc;g/mL His-tagged hACE2 protein was added to the wells, and then the diluted mAbs were added and mixed immediately. After 2&#x000a0;h of incubation at room temperature, plates were washed, and 0.08&#x000a0;&#x003bc;g/mL anti-His/HRP was added. After 1&#x000a0;h of incubation at room temperature, the chromogen solution was used as the substrate, and absorbance at 450&#x000a0;nm was measured by a microplate reader. The ACE2/RBD-binding inhibition rate was calculated by comparing to the mAbs negative control well.</p></sec><sec id="sec5.4.9"><title>Protein expression and purification for cryo-EM</title><p id="p0245">The SARS-CoV-2&#x000a0;S gene was synthesized by Sino Biological Inc. The DNA fragment encoding the ectodomain of S (residues 1-1208) was cloned into a pcDNA vector. Two stabilizing proline substitutions at residues 986-987 and a &#x0201c;GSAS&#x0201d; substitution at the furin cleavage site (residues 682&#x02013;685) were introduced as previously described to improve protein expression (<xref rid="bib57" ref-type="bibr">Wrapp et&#x000a0;al., 2020</xref>). A C-terminal T4 fibritin trimerization motif and an 8&#x000a0;&#x000d7; His tag were also engineered to stabilize trimer formation and facilitate protein purification.</p><p id="p0250">HEK293F cells were cultured in SMM 293T-I medium (Sino Biological Inc.) at 37&#x000b0;C, with 5% CO2 and 55% humidity. The plasmid was transfected into the cells using polyethylenimine (Polysciences) when the cell density reached 1&#x000a0;&#x000d7; 10<sup>6</sup> cells per mL. Four days after transfection, the conditioned media were collected by centrifugation at 500&#x000a0;&#x000d7; g, concentrated using a Hydrosart Ultrafilter (Sartorius), and exchanged into the binding buffer (25&#x000a0;mM Tris-HCl, pH 8.0, 200&#x000a0;mM NaCl). The S protein was subsequently isolated using the Ni-NTA resin, and purified using a Superose 6 10/300 gel filtration column (GE Life Sciences). The final buffer used for the gel filtration step is 20&#x000a0;mM HEPES, pH 7.2, 100&#x000a0;mM NaCl.</p><p id="p0255">To obtain BD23-Fab, BD-23 (2&#x000a0;mg/mL) was digested with papain (0.1&#x000a0;mg/mL) at 37&#x000b0;C for 2&#x000a0;h in 50&#x000a0;mM phosphate buffer saline, pH 7.0, 2&#x000a0;mM EDTA, and 5.5&#x000a0;mM cysteine. The reaction was terminated using 30&#x000a0;mM iodoacetamide at room temperature for 20&#x000a0;minutes. The Fc region was removed by protein A chromatography, and BD23-Fab was further purified using a Superdex 200 Increase 10/300 gel filtration column (GE Life Sciences) and eluted using the final buffer. Ab23-Fab was incubated with the purified S protein in a 1.5:1 molar ratio overnight on ice. After that, the complex was purified using the Superose 6 10/300 column and eluted with the final buffer.</p></sec><sec id="sec5.4.10"><title>Cryo-EM data collection and processing</title><p id="p0260">Holy-carbon gold grids (Quantifoil, R1.2/1.3) were glow-discharged with a Solarus 950 plasma cleaner (Gatan) for 30 s. Four-microliter aliquots of the S/BD23-Fab complex (0.6&#x000a0;mg/mL) were applied to the grids, blotted with filter paper at 4&#x000b0;C and 100% humidity, and plunged into the liquid ethane using a Vitrobot Mark IV (FEI). The grids were first screened on a 200 kV Talos Arctica microscope equipped with Ceta camera (FEI). Data were collected using a Titan Krios electron microscope (FEI) operated at 300 kV. Movies were recorded with a K2 Summit direct electron detector (Gatan) in the super-resolution mode using the SerialEM software (<xref rid="bib34" ref-type="bibr">Mastronarde, 2005</xref>). Statistics for data collection are summarized in (<xref rid="mmc3" ref-type="supplementary-material">Table S4</xref>).</p><p id="p0265">The workflow of data processing was illustrated in <xref rid="figs7" ref-type="fig">Figure&#x000a0;S7</xref>. Raw movie frames were aligned and averaged into motion-corrected summed images using MotionCor2 (<xref rid="bib65" ref-type="bibr">Zheng et&#x000a0;al., 2017</xref>). The Gctf program (v1.06) was used to estimate the contrast transfer function (CTF) parameters of the motion-corrected images (<xref rid="bib63" ref-type="bibr">Zhang, 2016</xref>). Relion (v3.07) was used for all the following data processing (<xref rid="bib68" ref-type="bibr">Zivanov et&#x000a0;al., 2018</xref>). The S trimer (PDB ID: 6VSB) was used as a reference for the 3D classifications. The local resolution map was analyzed using ResMap (<xref rid="bib78" ref-type="bibr">Kucukelbir et al., 2014</xref>) and displayed using UCSF Chimera (<xref rid="bib42" ref-type="bibr">Pettersen et&#x000a0;al., 2004</xref>).</p><p id="p0270">A structural model of BD23-Fab was generated using the Phyre2 server (<xref rid="bib25" ref-type="bibr">Kelley et&#x000a0;al., 2015</xref>). This BD23-Fab model and the S trimer structure (PDB ID: 6VSB) were docked into the cryo-EM density using UCSF Chimera. One round of rigid-body refinement was performed using the real-space refinement in Phenix (<xref rid="bib31" ref-type="bibr">Liebschner et&#x000a0;al., 2019</xref>). Further structure refinement of BD23-Fab was not performed due to limited resolution in this region. Nevertheless, it is evident that BD23-Fab engages an epitope on RBD that predominantly overlaps with the ACE2-binding site.</p></sec><sec id="sec5.4.11"><title>Pseudovirus neutralization assay</title><p id="p0275">The pseudovirus neutralization assays were performed using Huh-7 cell lines. Huh-7 are human hepatocellular carcinoma cells that express both ACE2 and TMPRSS2 (<xref rid="bib35" ref-type="bibr">Matsuyama et&#x000a0;al., 2018</xref>). Various concentrations of mAbs (3-fold serial dilution using DMEM, 50&#x000a0;&#x003bc;L aliquots) were mixed with the same volume of SARS-CoV-2 pseudovirus with a TCID<sub>50</sub> of 1.3&#x000a0;&#x000d7; 10<sup>4</sup> in a 96 well-plate. The mixture was incubated for 1&#x000a0;h at 37&#x000b0;C, supplied with 5% CO<sub>2</sub>. Negative control wells were supplied with 100&#x000a0;&#x003bc;L DMEM (1% (v/v) antibiotics, 25&#x000a0;nM HEPES, 10% (v/v) FBS). Positive control wells were supplied with 100&#x000a0;&#x003bc;L DMEM. Pre-mixed Huh-7 cells (100&#x000a0;&#x003bc;L, 2&#x000a0;&#x000d7; 10<sup>5</sup> in DMEM) were added to all wells, and the 96-well plates were incubated for 24&#x000a0;h at 37&#x000b0;C supplied with 5% CO<sub>2</sub>. After the incubation, 150&#x000a0;&#x003bc;L of supernatants were removed, and 100&#x000a0;&#x003bc;L D-luciferin reagent (Invitrogen) was added to each well and incubated for 2&#x000a0;mins. After the incubation, every well is mixed 10 times by pipetting, and 150&#x000a0;&#x003bc;L of the mixture was used to measure luciferase activity using a microplate spectrophotometer (Perkinelmer EnSight). The inhibition rate is calculated by comparing the OD value to the negative and positive control wells. IC<sub>50</sub> and IC<sub>80</sub> were determined by a four-parameter logistic regression using GraphPad Prism 8.0 (GraphPad Software Inc.). The raw data of a representative neutralization assay on BD-368-2 is described in <xref rid="mmc3" ref-type="supplementary-material">Table S5</xref>.</p></sec><sec id="sec5.4.12"><title>Authentic SARS-CoV-2 PRNT</title><p id="p0280">Plaque reduction neutralization test (PRNT) was performed using a clinical isolate of SARS-CoV-2 (BetaCoV/Wuhan/AMMS01/2020) (<xref rid="bib43" ref-type="bibr">Roehrig et&#x000a0;al., 2008</xref>). Briefly, 5-fold serial dilutions of mAbs were added to the same volume of approximately 100 PFU of SARS-CoV-2 and incubated for 1&#x000a0;h at 37&#x000b0;C. The mixture was added to a monolayer of Vero cells in a 24-well plate and incubated for 1&#x000a0;h at 37&#x000b0;C. The mixture was removed, 0.5&#x000a0;mL of 1.0% (w/v) LMP agarose (Promega) in 2&#x000a0;&#x000d7; DMEM supplied with 4% (v/v) FBS was added onto the infected cells. After further incubation at 37&#x000b0;C supplied with 5% CO<sub>2</sub> for 2&#x000a0;days, the wells were stained with 1% (w/v) crystal violet dissolved in 4% (v/v) formaldehyde to visualize the plaques. IC<sub>50</sub> values were determined using four-parameter logistic regression analysis by using GraphPad Prism 8.0 (GraphPad Software Inc.). All experiments were performed in a Biosafety Level 3 facility.</p></sec><sec id="sec5.4.13"><title>Authentic SARS-CoV-2 neutralization CPE assay</title><p id="p0285">A neutralization assay of authentic SARS-CoV-2 was performed using a cytopathic effect (CPE) assay. Briefly, various concentrations (3-fold serial dilution using DMEM) of mAbs were mixed with the same volume of 100 PFU of authentic SARS-CoV-2 and incubated at 37&#x000b0;C for 1 h. The mixture was added to a monolayer of Vero-E6 cells (5x10<sup>3</sup> cell per well) in a 96-well plate and incubated for 1&#x000a0;h at 37&#x000b0;C. The supernatant was removed, and 200&#x000a0;&#x003bc;L of DMEM supplied with 2% (v/v) FBS was added onto the infected cells. After incubation at 37&#x000b0;C supplied with 5% CO2 for 5&#x000a0;days, all wells examine for the CPE effect. All experiments were performed in a Biosafety Level 3 facility.</p></sec><sec id="sec5.4.14"><title>hACE2 <italic>in&#x000a0;vivo</italic> SARS-CoV-2 neutralization assay</title><p id="p0290">A total of 9 hACE2 transgenic mice were used in this study. The mice were equally split into three groups for prophylactic and therapeutic study, as well as the negative control. For the prophylactic group, BD-368-2 (20&#x000a0;mg/kg) was intraperitoneally injected one day before infection. For the therapeutic group, BD-368-2 (20&#x000a0;mg/kg) was intraperitoneally injected 2&#x000a0;h after infection. For the negative control group, HG1K (20&#x000a0;mg/kg, Sino Biology), which is an anti-influenza antibody, was intraperitoneally injected 2&#x000a0;h after infection. The hACE2 mice were inoculated intranasally with the SARS-CoV-2 stock virus with a dosage of 10<sup>5</sup> TCID<sub>50</sub>. Body weights were recorded daily for all infected mice for 5 continuous days. The mice were sacrificed at 5 dpi, and the lungs were collected for viral load analysis.</p><p id="p0295">Viral load detection was performed by qRT-PCR on RNA extracted from lung homogenate supernatants, as described previously (<xref rid="bib2" ref-type="bibr">Bao et&#x000a0;al., 2020</xref>). Briefly, lung homogenates were prepared by homogenizing perfused whole lung using an electric homogenizer. The supernatant was collected, and total RNA was extracted. A quantitative real-time reverse transcription-PCR (qRT-PCR) reactions were performed using the previously described primers and protocol. qRT-PCR was performed on each mouse with two replicates. All experiments were performed in a Biosafety Level 3 facility.</p></sec><sec id="sec5.4.15"><title>Epitope Binning</title><p id="p0300">Double-antibody sandwich ELISA was used to categorize the epitope of the identified potent neutralizing mAbs. Briefly, SARS-CoV-2 RBD-His Recombinant Protein (Biotinylated, Sino Biological Inc.) was diluted with PBST buffer to 3&#x000a0;&#x003bc;g/mL, and was captured by streptavidin probes. The neutralizing mAbs were diluted with PBST buffer to 133.3&#x000a0;nM each, and the primary antibody was first incubated with the RBD proteins. After 1&#x000a0;h incubation, the response value was measured by OCTET RED. After the measurement, the secondary antibody was added, and the response value was again measured after 30&#x000a0;mins incubation. Competition tolerance was calculated by the percentage increase of response after the secondary antibody was added, as shown in <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>. The column indicates the primary antibody, and the row indicates secondary antibodies. Competition tolerance larger than 50% indicates a high possibility of no overlapping epitope.</p></sec></sec><sec id="sec5.5"><title>Quantification and Statistical Analysis</title><sec id="sec5.5.1"><title>B cell scRNA-seq data analysis</title><p id="p0305">The raw fastq files were processed using the 10X Genomics CellRanger (3.1.0) pipeline. Reads produced from the 5&#x02032; gene expression profiling were aligned to the GRCh38 genome, and feature-barcode matrices were generated using &#x0201c;cellranger count&#x0201d; with default parameters. To filter out low-quality genes and cells, genes expressed in over 10 cells were retained, and cells were filtered based on the number of genes and the mitochondrial gene percentage to remove possible doublets. Cell types were identified using SingleR (<xref rid="bib75" ref-type="bibr">Aran et al., 2019</xref>) against a human immune reference dataset (<xref rid="bib81" ref-type="bibr">Monaco et al., 2019</xref>). Clusters of cells were visualized using T-distributed stochastic neighbor embedding (t-SNE) in Seurat (<xref rid="bib76" ref-type="bibr">Satija et al., 2015</xref>).</p></sec><sec id="sec5.5.2"><title>B cell scVDJ data analysis</title><p id="p0310">The raw fastq files were processed using 10X Genomics CellRanger (3.1.0) pipeline. 3&#x02032; ends of bases with quality scores lower than 30 were trimmed using cutadapt (<xref rid="bib72" ref-type="bibr">Martin, 2011</xref>). Contig assembly, annotation, and clonotype analysis were performed using &#x0201c;cellranger vdj&#x0201d; with the Cell Ranger V(D)J compatible reference:</p><p id="p0315">(refdata-cellranger-vdj-GRCh38-alts-ensembl-3.1.0).</p></sec><sec id="sec5.5.3"><title>Structural annotation of BCR repertoires</title><p id="p0320">Structures of the three CDR regions in heavy- and light chains were annotated using the SAAB+ pipeline (<xref rid="bib27" ref-type="bibr">Kovaltsuk et&#x000a0;al., 2020</xref>) with default parameters. SAAB+ utilizes SCALOP (<xref rid="bib56" ref-type="bibr">Wong et&#x000a0;al., 2019</xref>) to identify the canonical classes of CDR1 and CDR2 sequences. Structural annotations of CDR3 sequences were made by FREAD (<xref rid="bib10" ref-type="bibr">Choi and Deane, 2010</xref>) integrated in the SAAB+ pipeline.</p></sec><sec id="sec5.5.4"><title>Somatic hypermutation rate determination</title><p id="p0325">The mapping of V(D)J sequencing reads was performed by IgBlast-1.15.0 (<xref rid="bib61" ref-type="bibr">Ye et&#x000a0;al., 2013</xref>) against the germline reference (202007-1 release) downloaded from the international ImMunoGeneTics information system (IMGT) (<xref rid="bib18" ref-type="bibr">Giudicelli et&#x000a0;al., 2006</xref>). The hypermutation rate was calculated as <inline-formula><mml:math id="M1" altimg="si1.gif"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mo>+</mml:mo><mml:mi>g</mml:mi><mml:mi>a</mml:mi><mml:mi>p</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mspace width="0.25em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.25em"/><mml:mi>t</mml:mi><mml:mi>h</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.25em"/><mml:mi>q</mml:mi><mml:mi>u</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.25em"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>q</mml:mi><mml:mi>u</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>, in which the gaps were calculated as the number of base pairs in the insertion or deletion regions.</p></sec><sec id="sec5.5.5"><title>Ideal antibody selection</title><p id="p0330">All B cells belonging to enriched clonotypes that contain IgG1 were extracted and their corresponding cell type, somatic hypermutation (SHM) rate, and Ig class were recorded. The ideal antibody selection process strictly followed the criteria listed in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>D. The lineage within each clonotype was determined by the DNA mutation pattern as well as the Ig class. The lineage relationship would not interfere with ideal antibody selection, and only helps when selecting the mAbs sequences from a particular clonotype. When the B cells in the same clonotype did not share identical VDJ sequences, the DNA sequence of the most mature B cell in the lineage was usually selected for <italic>in&#x000a0;vitro</italic> expression. The lineage plot was drawn by igraph (<xref rid="bib77" ref-type="bibr">Csardi and Nepusz, 2006</xref>). The position of the cells on the graph has no physical meaning and was arbitrarily adjusted to group all ideal clonotypes on one side.</p></sec></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib79"><element-citation publication-type="journal" id="optx3p8rEYyTe"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>P.D.</given-names></name><name><surname>Afonine</surname><given-names>P.V.</given-names></name><name><surname>Bunk&#x000f3;czi</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>V.B.</given-names></name><name><surname>Davis</surname><given-names>I.W.</given-names></name><name><surname>Echols</surname><given-names>N.</given-names></name><name><surname>Headd</surname><given-names>J.J.</given-names></name><name><surname>Hung</surname><given-names>L.-W.</given-names></name><name><surname>Kapral</surname><given-names>G.J.</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>R.W.</given-names></name></person-group><article-title>PHENIX: A Comprehensive Python-based System for Macromolecular Structure Solution</article-title><source>Acta Crystallogr D. Biol. Crystallogr</source><volume>66</volume><year>2010</year><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">20124702</pub-id></element-citation></ref><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>An</surname><given-names>J.</given-names></name><name><surname>Liao</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>T.</given-names></name><name><surname>Qian</surname><given-names>S.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>H.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test</article-title><source>MedRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.26.20044222</pub-id><comment>Published online March 30, 2020</comment></element-citation></ref><ref id="bib75"><element-citation publication-type="journal" id="optZIByQOLZ8j"><person-group person-group-type="author"><name><surname>Aran</surname><given-names>D.</given-names></name><name><surname>Looney</surname><given-names>A.P.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>E.</given-names></name><name><surname>Fong</surname><given-names>V.</given-names></name><name><surname>Hsu</surname><given-names>A.</given-names></name><name><surname>Chak</surname><given-names>S.</given-names></name><name><surname>Naikawadi</surname><given-names>R.P.</given-names></name><name><surname>Wolters</surname><given-names>P.J.</given-names></name><name><surname>Abate</surname><given-names>A.R.</given-names></name></person-group><article-title>Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage</article-title><source>Nat. Immunol.</source><volume>20</volume><year>2019</year><fpage>163</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">30643263</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Yu</surname><given-names>P.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Qi</surname><given-names>F.</given-names></name></person-group><article-title>The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice</article-title><source>Nature</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41586-020-2312-y</pub-id><comment>Published online May 7, 2020</comment></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Bassing</surname><given-names>C.H.</given-names></name><name><surname>Swat</surname><given-names>W.</given-names></name><name><surname>Alt</surname><given-names>F.W.</given-names></name></person-group><article-title>The mechanism and regulation of chromosomal V(D)J recombination</article-title><source>Cell</source><volume>109</volume><issue>Suppl</issue><year>2002</year><fpage>S45</fpage><lpage>S55</lpage><pub-id pub-id-type="pmid">11983152</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Walker</surname><given-names>L.M.</given-names></name><name><surname>Phogat</surname><given-names>S.K.</given-names></name><name><surname>Chan-Hui</surname><given-names>P.Y.</given-names></name><name><surname>Wagner</surname><given-names>D.</given-names></name><name><surname>Phung</surname><given-names>P.</given-names></name><name><surname>Goss</surname><given-names>J.L.</given-names></name><name><surname>Wrin</surname><given-names>T.</given-names></name><name><surname>Simek</surname><given-names>M.D.</given-names></name><name><surname>Fling</surname><given-names>S.</given-names></name></person-group><article-title>Broad and potent neutralizing antibodies from an african donor reveal a new HIV-1 vaccine target</article-title><source>Science</source><volume>326</volume><year>2009</year><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">19729618</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>E.</given-names></name><name><surname>Cyranoski</surname><given-names>D.</given-names></name><name><surname>Mallapaty</surname><given-names>S.</given-names></name><name><surname>Stoye</surname><given-names>E.</given-names></name><name><surname>Tollefson</surname><given-names>J.</given-names></name></person-group><article-title>The coronavirus pandemic in five powerful charts</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>482</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">32203366</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>X.</given-names></name></person-group><article-title>COVID-19: immunopathology and its implications for therapy</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><year>2020</year><fpage>269</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">32273594</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Caskey</surname><given-names>M.</given-names></name><name><surname>Schoofs</surname><given-names>T.</given-names></name><name><surname>Gruell</surname><given-names>H.</given-names></name><name><surname>Settler</surname><given-names>A.</given-names></name><name><surname>Karagounis</surname><given-names>T.</given-names></name><name><surname>Kreider</surname><given-names>E.F.</given-names></name><name><surname>Murrell</surname><given-names>B.</given-names></name><name><surname>Pfeifer</surname><given-names>N.</given-names></name><name><surname>Nogueira</surname><given-names>L.</given-names></name><name><surname>Oliveira</surname><given-names>T.Y.</given-names></name></person-group><article-title>Antibody 10-1074 suppresses viremia in HIV-1-infected individuals</article-title><source>Nat. Med.</source><volume>23</volume><year>2017</year><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">28092665</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>J.F.W.</given-names></name><name><surname>Kok</surname><given-names>K.H.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name><name><surname>To</surname><given-names>K.K.W.</given-names></name><name><surname>Yuan</surname><given-names>S.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>Y.</given-names></name></person-group><article-title>Convalescent plasma as a potential therapy for COVID-19</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><year>2020</year><fpage>398</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">32113510</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y.</given-names></name><name><surname>Deane</surname><given-names>C.M.</given-names></name></person-group><article-title>FREAD revisited: Accurate loop structure prediction using a database search algorithm</article-title><source>Proteins</source><volume>78</volume><year>2010</year><fpage>1431</fpage><lpage>1440</lpage><pub-id pub-id-type="pmid">20034110</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Pedotti</surname><given-names>M.</given-names></name><name><surname>Simonelli</surname><given-names>L.</given-names></name><name><surname>Agnihothram</surname><given-names>S.</given-names></name><name><surname>Fett</surname><given-names>C.</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>B.</given-names></name><name><surname>Foglierini</surname><given-names>M.</given-names></name><name><surname>Agatic</surname><given-names>G.</given-names></name><name><surname>Vanzetta</surname><given-names>F.</given-names></name></person-group><article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>112</volume><year>2015</year><fpage>10473</fpage><lpage>10478</lpage><pub-id pub-id-type="pmid">26216974</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Misasi</surname><given-names>J.</given-names></name><name><surname>Mulangu</surname><given-names>S.</given-names></name><name><surname>Stanley</surname><given-names>D.A.</given-names></name><name><surname>Kanekiyo</surname><given-names>M.</given-names></name><name><surname>Wollen</surname><given-names>S.</given-names></name><name><surname>Ploquin</surname><given-names>A.</given-names></name><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name><name><surname>Staupe</surname><given-names>R.P.</given-names></name><name><surname>Bailey</surname><given-names>M.</given-names></name></person-group><article-title>Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody</article-title><source>Science</source><volume>351</volume><year>2016</year><fpage>1339</fpage><lpage>1342</lpage><pub-id pub-id-type="pmid">26917593</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Croote</surname><given-names>D.</given-names></name><name><surname>Darmanis</surname><given-names>S.</given-names></name><name><surname>Nadeau</surname><given-names>K.C.</given-names></name><name><surname>Quake</surname><given-names>S.R.</given-names></name></person-group><article-title>High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes</article-title><source>Science</source><volume>362</volume><year>2018</year><fpage>1306</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">30545888</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="book" id="opta3kJgdvhzW"><person-group person-group-type="author"><name><surname>Csardi</surname><given-names>G.</given-names></name><name><surname>Nepusz</surname><given-names>T.</given-names></name></person-group><chapter-title>igraph - The network analysis package</chapter-title><year>2006</year><ext-link ext-link-type="uri" xlink:href="https://igraph.org/" id="interref0010">https://igraph.org/</ext-link></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>DeKosky</surname><given-names>B.J.</given-names></name><name><surname>Lungu</surname><given-names>O.I.</given-names></name><name><surname>Park</surname><given-names>D.</given-names></name><name><surname>Johnson</surname><given-names>E.L.</given-names></name><name><surname>Charab</surname><given-names>W.</given-names></name><name><surname>Chrysostomou</surname><given-names>C.</given-names></name><name><surname>Kuroda</surname><given-names>D.</given-names></name><name><surname>Ellington</surname><given-names>A.D.</given-names></name><name><surname>Ippolito</surname><given-names>G.C.</given-names></name><name><surname>Gray</surname><given-names>J.J.</given-names></name><name><surname>Georgiou</surname><given-names>G.</given-names></name></person-group><article-title>Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>113</volume><year>2016</year><fpage>E2636</fpage><lpage>E2645</lpage><pub-id pub-id-type="pmid">27114511</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Ekiert</surname><given-names>D.C.</given-names></name><name><surname>Bhabha</surname><given-names>G.</given-names></name><name><surname>Elsliger</surname><given-names>M.A.</given-names></name><name><surname>Friesen</surname><given-names>R.H.E.</given-names></name><name><surname>Jongeneelen</surname><given-names>M.</given-names></name><name><surname>Throsby</surname><given-names>M.</given-names></name><name><surname>Goudsmit</surname><given-names>J.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Antibody recognition of a highly conserved influenza virus epitope</article-title><source>Science</source><volume>324</volume><year>2009</year><fpage>246</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">19251591</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>El Debs</surname><given-names>B.</given-names></name><name><surname>Utharala</surname><given-names>R.</given-names></name><name><surname>Balyasnikova</surname><given-names>I.V.</given-names></name><name><surname>Griffiths</surname><given-names>A.D.</given-names></name><name><surname>Merten</surname><given-names>C.A.</given-names></name></person-group><article-title>Functional single-cell hybridoma screening using droplet-based microfluidics</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>109</volume><year>2012</year><fpage>11570</fpage><lpage>11575</lpage><pub-id pub-id-type="pmid">22753519</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal" id="opt1PbtE4tl54"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P.</given-names></name><name><surname>Lohkamp</surname><given-names>B.</given-names></name><name><surname>Scott</surname><given-names>W.G.</given-names></name><name><surname>Cowtan</surname><given-names>K.</given-names></name></person-group><article-title>Features and development of Coot</article-title><source>Acta Crystallogr D. Biol. Crystallogr</source><volume>66</volume><year>2010</year><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">20383002</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Giudicelli</surname><given-names>V.</given-names></name><name><surname>Duroux</surname><given-names>P.</given-names></name><name><surname>Ginestoux</surname><given-names>C.</given-names></name><name><surname>Folch</surname><given-names>G.</given-names></name><name><surname>Jabado-Michaloud</surname><given-names>J.</given-names></name><name><surname>Chaume</surname><given-names>D.</given-names></name><name><surname>Lefranc</surname><given-names>M.-P.</given-names></name></person-group><article-title>IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T&#x000a0;cell receptor nucleotide sequences</article-title><source>Nucleic Acids Res.</source><volume>34</volume><year>2006</year><fpage>D781</fpage><lpage>D784</lpage><pub-id pub-id-type="pmid">16381979</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>L.D.</given-names></name><name><surname>Chen</surname><given-names>Y.J.J.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Chaudhuri</surname><given-names>S.</given-names></name><name><surname>Hsiao</surname><given-names>Y.C.</given-names></name><name><surname>Schneider</surname><given-names>K.</given-names></name><name><surname>Hoi</surname><given-names>K.H.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Guerrero</surname><given-names>S.</given-names></name><name><surname>Jaiswal</surname><given-names>B.S.</given-names></name></person-group><article-title>Massively parallel single-cell B-cell receptor sequencing enables rapid discovery of diverse antigen-reactive antibodies</article-title><source>Commun. Biol.</source><volume>2</volume><year>2019</year><fpage>304</fpage><pub-id pub-id-type="pmid">31428692</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Gorny</surname><given-names>M.K.</given-names></name><name><surname>Wang</surname><given-names>X.H.</given-names></name><name><surname>Williams</surname><given-names>C.</given-names></name><name><surname>Volsky</surname><given-names>B.</given-names></name><name><surname>Revesz</surname><given-names>K.</given-names></name><name><surname>Witover</surname><given-names>B.</given-names></name><name><surname>Burda</surname><given-names>S.</given-names></name><name><surname>Urbanski</surname><given-names>M.</given-names></name><name><surname>Nyambi</surname><given-names>P.</given-names></name><name><surname>Krachmarov</surname><given-names>C.</given-names></name></person-group><article-title>Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1</article-title><source>Mol. Immunol.</source><volume>46</volume><year>2009</year><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="pmid">18952295</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>N.H.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name></person-group><article-title>SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Horns</surname><given-names>F.</given-names></name><name><surname>Dekker</surname><given-names>C.L.</given-names></name><name><surname>Quake</surname><given-names>S.R.</given-names></name></person-group><article-title>Memory B Cell Activation, Broad Anti-influenza Antibodies, and Bystander Activation Revealed by Single-Cell Transcriptomics</article-title><source>Cell Rep.</source><volume>30</volume><year>2020</year><fpage>905</fpage><lpage>913</lpage><pub-id pub-id-type="pmid">31968262</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>W.C.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Santelli</surname><given-names>E.</given-names></name><name><surname>Sui</surname><given-names>J.</given-names></name><name><surname>Jaroszewski</surname><given-names>L.</given-names></name><name><surname>Stec</surname><given-names>B.</given-names></name><name><surname>Farzan</surname><given-names>M.</given-names></name><name><surname>Marasco</surname><given-names>W.A.</given-names></name><name><surname>Liddington</surname><given-names>R.C.</given-names></name></person-group><article-title>Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>281</volume><year>2006</year><fpage>34610</fpage><lpage>34616</lpage><pub-id pub-id-type="pmid">16954221</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Irani</surname><given-names>V.</given-names></name><name><surname>Guy</surname><given-names>A.J.</given-names></name><name><surname>Andrew</surname><given-names>D.</given-names></name><name><surname>Beeson</surname><given-names>J.G.</given-names></name><name><surname>Ramsland</surname><given-names>P.A.</given-names></name><name><surname>Richards</surname><given-names>J.S.</given-names></name></person-group><article-title>Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases</article-title><source>Mol. Immunol.</source><volume>67</volume><issue>2 Pt A</issue><year>2015</year><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">25900877</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Kelley</surname><given-names>L.A.</given-names></name><name><surname>Mezulis</surname><given-names>S.</given-names></name><name><surname>Yates</surname><given-names>C.M.</given-names></name><name><surname>Wass</surname><given-names>M.N.</given-names></name><name><surname>Sternberg</surname><given-names>M.J.E.</given-names></name></person-group><article-title>The Phyre2 web portal for protein modeling, prediction and analysis</article-title><source>Nat. Protoc.</source><volume>10</volume><year>2015</year><fpage>845</fpage><lpage>858</lpage><pub-id pub-id-type="pmid">25950237</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Kovaltsuk</surname><given-names>A.</given-names></name><name><surname>Krawczyk</surname><given-names>K.</given-names></name><name><surname>Galson</surname><given-names>J.D.</given-names></name><name><surname>Kelly</surname><given-names>D.F.</given-names></name><name><surname>Deane</surname><given-names>C.M.</given-names></name><name><surname>Tr&#x000fc;ck</surname><given-names>J.</given-names></name></person-group><article-title>How B-cell receptor repertoire sequencing can be enriched with structural antibody data</article-title><source>Front. Immunol.</source><volume>8</volume><year>2017</year><fpage>1753</fpage><pub-id pub-id-type="pmid">29276518</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Kovaltsuk</surname><given-names>A.</given-names></name><name><surname>Raybould</surname><given-names>M.I.J.</given-names></name><name><surname>Wong</surname><given-names>W.K.</given-names></name><name><surname>Marks</surname><given-names>C.</given-names></name><name><surname>Kelm</surname><given-names>S.</given-names></name><name><surname>Snowden</surname><given-names>J.</given-names></name><name><surname>Tr&#x000fc;ck</surname><given-names>J.</given-names></name><name><surname>Deane</surname><given-names>C.M.</given-names></name></person-group><article-title>Structural diversity of B-cell receptor repertoires along the B-cell differentiation axis in humans and mice</article-title><source>PLoS Comput. Biol.</source><volume>16</volume><year>2020</year><fpage>e1007636</fpage><pub-id pub-id-type="pmid">32069281</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Krawczyk</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Baker</surname><given-names>T.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Deane</surname><given-names>C.M.</given-names></name></person-group><article-title>Improving B-cell epitope prediction and its application to global antibody-antigen docking</article-title><source>Bioinformatics</source><volume>30</volume><year>2014</year><fpage>2288</fpage><lpage>2294</lpage><pub-id pub-id-type="pmid">24753488</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal" id="optAOlRLHjmwa"><person-group person-group-type="author"><name><surname>Kucukelbir</surname><given-names>A.</given-names></name><name><surname>Sigworth</surname><given-names>F.J.</given-names></name><name><surname>Tagare</surname><given-names>H.D.</given-names></name></person-group><article-title>Quantifying the local resolution of cryo-EM density maps</article-title><source>Nat. Methods</source><volume>11</volume><year>2014</year><fpage>63</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">24213166</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H.X.</given-names></name><name><surname>Levesque</surname><given-names>M.C.</given-names></name><name><surname>Nagel</surname><given-names>A.</given-names></name><name><surname>Dixon</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Walter</surname><given-names>E.</given-names></name><name><surname>Parks</surname><given-names>R.</given-names></name><name><surname>Whitesides</surname><given-names>J.</given-names></name><name><surname>Marshall</surname><given-names>D.J.</given-names></name><name><surname>Hwang</surname><given-names>K.K.</given-names></name></person-group><article-title>High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies</article-title><source>J.&#x000a0;Virol. Methods</source><volume>158</volume><year>2009</year><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">19428587</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Liebschner</surname><given-names>D.</given-names></name><name><surname>Afonine</surname><given-names>P.V.</given-names></name><name><surname>Baker</surname><given-names>M.L.</given-names></name><name><surname>Bunk&#x000f3;czi</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>V.B.</given-names></name><name><surname>Croll</surname><given-names>T.I.</given-names></name><name><surname>Hintze</surname><given-names>B.</given-names></name><name><surname>Hung</surname><given-names>L.W.</given-names></name><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>McCoy</surname><given-names>A.J.</given-names></name></person-group><article-title>Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix</article-title><source>Acta Crystallogr. D Struct. Biol.</source><volume>75</volume><year>2019</year><fpage>861</fpage><lpage>877</lpage><pub-id pub-id-type="pmid">31588918</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>N.C.</given-names></name><name><surname>Tsang</surname><given-names>O.T.-Y.</given-names></name><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Perera</surname><given-names>R.A.P.M.</given-names></name><name><surname>Leung</surname><given-names>W.S.</given-names></name><name><surname>So</surname><given-names>R.T.Y.</given-names></name><name><surname>Chan</surname><given-names>J.M.C.</given-names></name><name><surname>Yip</surname><given-names>G.K.</given-names></name><name><surname>Chik</surname><given-names>T.S.H.</given-names></name></person-group><article-title>Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.15.993097</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Marasca</surname><given-names>R.</given-names></name><name><surname>Vaccari</surname><given-names>P.</given-names></name><name><surname>Luppi</surname><given-names>M.</given-names></name><name><surname>Zucchini</surname><given-names>P.</given-names></name><name><surname>Castelli</surname><given-names>I.</given-names></name><name><surname>Barozzi</surname><given-names>P.</given-names></name><name><surname>Cuoghi</surname><given-names>A.</given-names></name><name><surname>Torelli</surname><given-names>G.</given-names></name></person-group><article-title>Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma</article-title><source>Am. J. Pathol.</source><volume>159</volume><year>2001</year><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">11438472</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal" id="optvEYoVoEBMc"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M.</given-names></name></person-group><article-title>Cutadapt removes adapter sequences from high-throughput sequencing reads</article-title><source>Embnet J.</source><volume>17</volume><year>2011</year><fpage>10</fpage><lpage>12</lpage></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Mastronarde</surname><given-names>D.N.</given-names></name></person-group><article-title>Automated electron microscope tomography using robust prediction of specimen movements</article-title><source>J.&#x000a0;Struct. Biol.</source><volume>152</volume><year>2005</year><fpage>36</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">16182563</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Terada</surname><given-names>Y.</given-names></name><name><surname>Kawachi</surname><given-names>K.</given-names></name><name><surname>Fukushi</surname><given-names>S.</given-names></name><name><surname>Kamitani</surname><given-names>W.</given-names></name></person-group><article-title>Middle East Respiratory Syndrome Coronavirus Spike Protein Is Not Activated Directly by Cellular Furin during Viral Entry into Target Cells</article-title><source>J.&#x000a0;Virol.</source><volume>92</volume><year>2018</year><comment>e00683&#x02013;e18</comment></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>McCray</surname><given-names>P.B.</given-names><suffix>Jr.</suffix></name><name><surname>Pewe</surname><given-names>L.</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name><surname>Hickey</surname><given-names>M.</given-names></name><name><surname>Manzel</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Netland</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>H.P.</given-names></name><name><surname>Halabi</surname><given-names>C.</given-names></name><name><surname>Sigmund</surname><given-names>C.D.</given-names></name></person-group><article-title>Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus</article-title><source>J.&#x000a0;Virol.</source><volume>81</volume><year>2007</year><fpage>813</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">17079315</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Methot</surname><given-names>S.P.</given-names></name><name><surname>Di Noia</surname><given-names>J.M.</given-names></name></person-group><article-title>Molecular Mechanisms of Somatic Hypermutation and Class Switch Recombination</article-title><source>Adv. Immunol.</source><volume>133</volume><year>2017</year><fpage>37</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">28215280</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Moir</surname><given-names>S.</given-names></name><name><surname>Fauci</surname><given-names>A.S.</given-names></name></person-group><article-title>B-cell exhaustion in HIV infection: the role of immune activation</article-title><source>Curr. Opin. HIV AIDS</source><volume>9</volume><year>2014</year><fpage>472</fpage><lpage>477</lpage><pub-id pub-id-type="pmid">25023621</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal" id="optySmGqrqMW4"><person-group person-group-type="author"><name><surname>Monaco</surname><given-names>G.</given-names></name><name><surname>Lee</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Mustafah</surname><given-names>S.</given-names></name><name><surname>Hwang</surname><given-names>Y.Y.</given-names></name><name><surname>Carr&#x000e9;</surname><given-names>C.</given-names></name><name><surname>Burdin</surname><given-names>N.</given-names></name><name><surname>Visan</surname><given-names>L.</given-names></name><name><surname>Ceccarelli</surname><given-names>M.</given-names></name><name><surname>Poidinger</surname><given-names>M.</given-names></name></person-group><article-title>RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell Types</article-title><source>Cell Reports</source><volume>26</volume><year>2019</year><fpage>1627</fpage><lpage>1640.e7</lpage><pub-id pub-id-type="pmid">30726743</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Murugan</surname><given-names>R.</given-names></name><name><surname>Buchauer</surname><given-names>L.</given-names></name><name><surname>Triller</surname><given-names>G.</given-names></name><name><surname>Kreschel</surname><given-names>C.</given-names></name><name><surname>Costa</surname><given-names>G.</given-names></name><name><surname>Mart&#x000ed;</surname><given-names>G.P.</given-names></name><name><surname>Imkeller</surname><given-names>K.</given-names></name><name><surname>Busse</surname><given-names>C.E.</given-names></name><name><surname>Chakravarty</surname><given-names>S.</given-names></name><name><surname>Kim Lee Sim</surname><given-names>B.</given-names></name></person-group><article-title>Clonal selection drives protective memory B cell responses in controlled human malaria infection</article-title><source>Sci. Immunol.</source><volume>3</volume><year>2018</year><fpage>eaap8029</fpage><pub-id pub-id-type="pmid">29453292</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>C.</given-names></name><name><surname>Hao</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Nie</surname><given-names>L.</given-names></name><name><surname>Qin</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>680</fpage><lpage>686</lpage><pub-id pub-id-type="pmid">32207377</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Qu</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Yan</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Liang</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name></person-group><article-title>Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model</article-title><source>Emerg. Microbes Infect.</source><volume>8</volume><year>2019</year><fpage>749</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">31130109</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>E.F.</given-names></name><name><surname>Goddard</surname><given-names>T.D.</given-names></name><name><surname>Huang</surname><given-names>C.C.</given-names></name><name><surname>Couch</surname><given-names>G.S.</given-names></name><name><surname>Greenblatt</surname><given-names>D.M.</given-names></name><name><surname>Meng</surname><given-names>E.C.</given-names></name><name><surname>Ferrin</surname><given-names>T.E.</given-names></name></person-group><article-title>UCSF Chimera--a visualization system for exploratory research and analysis</article-title><source>J.&#x000a0;Comput. Chem.</source><volume>25</volume><year>2004</year><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal" id="optXKkUFPoX3p"><person-group person-group-type="author"><name><surname>Prabakaran</surname><given-names>P.</given-names></name><name><surname>Gan</surname><given-names>J.</given-names></name><name><surname>Feng</surname><given-names>Y.</given-names></name><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Choudhry</surname><given-names>V.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Ji</surname><given-names>X.</given-names></name><name><surname>Dimitrov</surname><given-names>D.S.</given-names></name></person-group><article-title>Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody</article-title><source>J. Biol. Chem.</source><volume>281</volume><year>2006</year><fpage>15829</fpage><lpage>15836</lpage><pub-id pub-id-type="pmid">16597622</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Roehrig</surname><given-names>J.T.</given-names></name><name><surname>Hombach</surname><given-names>J.</given-names></name><name><surname>Barrett</surname><given-names>A.D.T.</given-names></name></person-group><article-title>Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses</article-title><source>Viral Immunol.</source><volume>21</volume><year>2008</year><fpage>123</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">18476771</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal" id="optf5Tl7WiwXi"><person-group person-group-type="author"><name><surname>Satija</surname><given-names>R.</given-names></name><name><surname>Farrell</surname><given-names>J.A.</given-names></name><name><surname>Gennert</surname><given-names>D.</given-names></name><name><surname>Schier</surname><given-names>A.F.</given-names></name><name><surname>Regev</surname><given-names>A.</given-names></name></person-group><article-title>Spatial reconstruction of single-cell gene expression data</article-title><source>Nature Biotechnology</source><volume>33</volume><year>2015</year><fpage>495</fpage><lpage>502</lpage></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Mouquet</surname><given-names>H.</given-names></name><name><surname>Feldhahn</surname><given-names>N.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Velinzon</surname><given-names>K.</given-names></name><name><surname>Pietzsch</surname><given-names>J.</given-names></name><name><surname>Ott</surname><given-names>R.G.</given-names></name><name><surname>Anthony</surname><given-names>R.M.</given-names></name><name><surname>Zebroski</surname><given-names>H.</given-names></name><name><surname>Hurley</surname><given-names>A.</given-names></name></person-group><article-title>Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals</article-title><source>Nature</source><volume>458</volume><year>2009</year><fpage>636</fpage><lpage>640</lpage><pub-id pub-id-type="pmid">19287373</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Seifert</surname><given-names>M.</given-names></name><name><surname>K&#x000fc;ppers</surname><given-names>R.</given-names></name></person-group><article-title>Human memory B cells</article-title><source>Leukemia</source><volume>30</volume><year>2016</year><fpage>2283</fpage><lpage>2292</lpage><pub-id pub-id-type="pmid">27499139</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Sela-Culang</surname><given-names>I.</given-names></name><name><surname>Benhnia</surname><given-names>M.R.E.I.</given-names></name><name><surname>Matho</surname><given-names>M.H.</given-names></name><name><surname>Kaever</surname><given-names>T.</given-names></name><name><surname>Maybeno</surname><given-names>M.</given-names></name><name><surname>Schlossman</surname><given-names>A.</given-names></name><name><surname>Nimrod</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Xiang</surname><given-names>Y.</given-names></name><name><surname>Zajonc</surname><given-names>D.</given-names></name></person-group><article-title>Using a combined computational-experimental approach to predict antibody-specific B cell epitopes</article-title><source>Structure</source><volume>22</volume><year>2014</year><fpage>646</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">24631463</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="optEXpb8pMm2J"><person-group person-group-type="author"><name><surname>Setliff</surname><given-names>I.</given-names></name><name><surname>Shiakolas</surname><given-names>A.R.</given-names></name><name><surname>Pilewski</surname><given-names>K.A.</given-names></name><name><surname>Murji</surname><given-names>A.A.</given-names></name><name><surname>Mapengo</surname><given-names>R.E.</given-names></name><name><surname>Janowska</surname><given-names>K.</given-names></name><name><surname>Richardson</surname><given-names>S.</given-names></name><name><surname>Oosthuysen</surname><given-names>C.</given-names></name><name><surname>Raju</surname><given-names>N.</given-names></name><name><surname>Ronsard</surname><given-names>L.</given-names></name></person-group><article-title>High-Throughput Mapping of B Cell Receptor Sequences to Antigen Specificity</article-title><source>Cell</source><volume>179</volume><year>2019</year><fpage>1636</fpage><lpage>1646.e15</lpage><pub-id pub-id-type="pmid">31787378</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Setthapramote</surname><given-names>C.</given-names></name><name><surname>Sasaki</surname><given-names>T.</given-names></name><name><surname>Puiprom</surname><given-names>O.</given-names></name><name><surname>Limkittikul</surname><given-names>K.</given-names></name><name><surname>Pitaksajjakul</surname><given-names>P.</given-names></name><name><surname>Pipattanaboon</surname><given-names>C.</given-names></name><name><surname>Sasayama</surname><given-names>M.</given-names></name><name><surname>Leuangwutiwong</surname><given-names>P.</given-names></name><name><surname>Phumratanaprapin</surname><given-names>W.</given-names></name><name><surname>Chamnachanan</surname><given-names>S.</given-names></name></person-group><article-title>Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>423</volume><year>2012</year><fpage>867</fpage><lpage>872</lpage><pub-id pub-id-type="pmid">22713454</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>D.</given-names></name><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Xing</surname><given-names>L.</given-names></name></person-group><article-title>Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1582</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">32219428</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>S.</given-names></name><name><surname>Lu</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Ying</surname><given-names>T.</given-names></name></person-group><article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>382</fpage><lpage>385</lpage><pub-id pub-id-type="pmid">32065055</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Tiller</surname><given-names>T.</given-names></name><name><surname>Meffre</surname><given-names>E.</given-names></name><name><surname>Yurasov</surname><given-names>S.</given-names></name><name><surname>Tsuiji</surname><given-names>M.</given-names></name><name><surname>Nussenzweig</surname><given-names>M.C.</given-names></name><name><surname>Wardemann</surname><given-names>H.</given-names></name></person-group><article-title>Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning</article-title><source>J.&#x000a0;Immunol. Methods</source><volume>329</volume><year>2008</year><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="pmid">17996249</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Vidarsson</surname><given-names>G.</given-names></name><name><surname>Dekkers</surname><given-names>G.</given-names></name><name><surname>Rispens</surname><given-names>T.</given-names></name></person-group><article-title>IgG subclasses and allotypes: from structure to effector functions</article-title><source>Front. Immunol.</source><volume>5</volume><year>2014</year><fpage>520</fpage><pub-id pub-id-type="pmid">25368619</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>A.C.</given-names></name><name><surname>Park</surname><given-names>Y.J.</given-names></name><name><surname>Tortorici</surname><given-names>M.A.</given-names></name><name><surname>Wall</surname><given-names>A.</given-names></name><name><surname>McGuire</surname><given-names>A.T.</given-names></name><name><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>281</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Chappell</surname><given-names>J.D.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Kanekiyo</surname><given-names>M.</given-names></name><name><surname>Becker</surname><given-names>M.M.</given-names></name><name><surname>van Doremalen</surname><given-names>N.</given-names></name><name><surname>Fischer</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name></person-group><article-title>Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape</article-title><source>J.&#x000a0;Virol.</source><volume>92</volume><year>2018</year><fpage>1</fpage><lpage>21</lpage></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Drabek</surname><given-names>D.</given-names></name><name><surname>Okba</surname><given-names>N.M.A.</given-names></name><name><surname>Haperen</surname><given-names>R. van</given-names></name><name><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><name><surname>Kuppeveld</surname><given-names>F.J.M. van</given-names></name><name><surname>Haagmans</surname><given-names>B.L.</given-names></name><name><surname>Grosveld</surname><given-names>F.</given-names></name><name><surname>Bosch</surname><given-names>B.-J.</given-names></name></person-group><article-title>A human monoclonal antibody blocking SARS-CoV-2 infection</article-title><source>Nat. Commun.</source><year>2020</year><pub-id pub-id-type="doi">10.1038/s41467-020-16256-y</pub-id><comment>Published online May 4, 2020</comment></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Wardemann</surname><given-names>H.</given-names></name><name><surname>Yurasov</surname><given-names>S.</given-names></name><name><surname>Schaefer</surname><given-names>A.</given-names></name><name><surname>Young</surname><given-names>J.W.</given-names></name><name><surname>Meffre</surname><given-names>E.</given-names></name><name><surname>Nussenzweig</surname><given-names>M.C.</given-names></name></person-group><article-title>Predominant autoantibody production by early human B cell precursors</article-title><source>Science</source><volume>301</volume><year>2003</year><fpage>1374</fpage><lpage>1377</lpage><pub-id pub-id-type="pmid">12920303</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>W.K.</given-names></name><name><surname>Georges</surname><given-names>G.</given-names></name><name><surname>Ros</surname><given-names>F.</given-names></name><name><surname>Kelm</surname><given-names>S.</given-names></name><name><surname>Lewis</surname><given-names>A.P.</given-names></name><name><surname>Taddese</surname><given-names>B.</given-names></name><name><surname>Leem</surname><given-names>J.</given-names></name><name><surname>Deane</surname><given-names>C.M.</given-names></name></person-group><article-title>SCALOP: sequence-based antibody canonical loop structure annotation</article-title><source>Bioinformatics</source><volume>35</volume><year>2019</year><fpage>1774</fpage><lpage>1776</lpage><pub-id pub-id-type="pmid">30321295</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="optkYbrfdnLuO"><person-group person-group-type="author"><name><surname>Wrammert</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>K.</given-names></name><name><surname>Miller</surname><given-names>J.</given-names></name><name><surname>Langley</surname><given-names>W.A.</given-names></name><name><surname>Kokko</surname><given-names>K.</given-names></name><name><surname>Larsen</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>N.Y.</given-names></name><name><surname>Mays</surname><given-names>I.</given-names></name><name><surname>Garman</surname><given-names>L.</given-names></name><name><surname>Helms</surname><given-names>C.</given-names></name></person-group><article-title>Rapid cloning of high-affinity human monoclonal antibodies against influenza virus</article-title><source>Nature</source><volume>453</volume><year>2008</year><fpage>667</fpage><lpage>671</lpage><pub-id pub-id-type="pmid">18449194</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Wrapp</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>N.</given-names></name><name><surname>Corbett</surname><given-names>K.S.</given-names></name><name><surname>Goldsmith</surname><given-names>J.A.</given-names></name><name><surname>Hsieh</surname><given-names>C.L.</given-names></name><name><surname>Abiona</surname><given-names>O.</given-names></name><name><surname>Graham</surname><given-names>B.S.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name></person-group><article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title><source>Science</source><volume>80</volume><issue>361</issue><year>2020</year><fpage>1260</fpage><lpage>1263</lpage></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.G.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>Z.W.</given-names></name><name><surname>Tian</surname><given-names>J.H.</given-names></name><name><surname>Pei</surname><given-names>Y.Y.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Jia</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Antibodies and vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Emerg. Microbes Infect.</source><volume>8</volume><year>2019</year><fpage>841</fpage><lpage>856</lpage><pub-id pub-id-type="pmid">31169078</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X.H.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name><name><surname>Tong</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.X.</given-names></name><name><surname>Zhang</surname><given-names>L.F.</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.L.</given-names></name><name><surname>Ma</surname><given-names>C.M.</given-names></name></person-group><article-title>Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection</article-title><source>Comp. Med.</source><volume>57</volume><year>2007</year><fpage>450</fpage><lpage>459</lpage><pub-id pub-id-type="pmid">17974127</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Ma</surname><given-names>N.</given-names></name><name><surname>Madden</surname><given-names>T.L.</given-names></name><name><surname>Ostell</surname><given-names>J.M.</given-names></name></person-group><article-title>IgBLAST: an immunoglobulin variable domain sequence analysis tool</article-title><source>Nucleic Acids Res.</source><volume>41</volume><year>2013</year><fpage>W34</fpage><lpage>W40</lpage><pub-id pub-id-type="pmid">23671333</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>N.C.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Lee</surname><given-names>C.-C.D.</given-names></name><name><surname>So</surname><given-names>R.T.Y.</given-names></name><name><surname>Lv</surname><given-names>H.</given-names></name><name><surname>Mok</surname><given-names>C.K.P.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV</article-title><source>Science</source><volume>368</volume><year>2020</year><fpage>630</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">32245784</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K.</given-names></name></person-group><article-title>Gctf: Real-time CTF determination and correction</article-title><source>J.&#x000a0;Struct. Biol.</source><volume>193</volume><year>2016</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">26592709</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Cui</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>G.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Cai</surname><given-names>C.</given-names></name><name><surname>He</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>Detectable SARS-CoV-2 viral RNA in feces of three children during recovery period of COVID-19 pneumonia</article-title><source>J.&#x000a0;Med. Virol.</source><year>2020</year><pub-id pub-id-type="doi">10.1002/jmv.25795</pub-id><comment>Published online March 29, 2020</comment></element-citation></ref><ref id="bib65"><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>S.Q.</given-names></name><name><surname>Palovcak</surname><given-names>E.</given-names></name><name><surname>Armache</surname><given-names>J.P.</given-names></name><name><surname>Verba</surname><given-names>K.A.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Agard</surname><given-names>D.A.</given-names></name></person-group><article-title>MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy</article-title><source>Nat. Methods</source><volume>14</volume><year>2017</year><fpage>331</fpage><lpage>332</lpage><pub-id pub-id-type="pmid">28250466</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>X.G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Si</surname><given-names>H.R.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>C.L.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z.</given-names></name><name><surname>Chakraborti</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.</given-names></name><name><surname>Sheahan</surname><given-names>T.</given-names></name><name><surname>Xiao</surname><given-names>X.</given-names></name><name><surname>Hensley</surname><given-names>L.E.</given-names></name><name><surname>Prabakaran</surname><given-names>P.</given-names></name><name><surname>Rockx</surname><given-names>B.</given-names></name><name><surname>Sidorov</surname><given-names>I.A.</given-names></name></person-group><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>104</volume><year>2007</year><fpage>12123</fpage><lpage>12128</lpage><pub-id pub-id-type="pmid">17620608</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Zivanov</surname><given-names>J.</given-names></name><name><surname>Nakane</surname><given-names>T.</given-names></name><name><surname>Forsberg</surname><given-names>B.O.</given-names></name><name><surname>Kimanius</surname><given-names>D.</given-names></name><name><surname>Hagen</surname><given-names>W.J.H.</given-names></name><name><surname>Lindahl</surname><given-names>E.</given-names></name><name><surname>Scheres</surname><given-names>S.H.W.</given-names></name></person-group><article-title>New tools for automated high-resolution cryo-EM structure determination in RELION-3</article-title><source>eLife</source><volume>7</volume><year>2018</year><fpage>e4216</fpage></element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental Information</title><p id="p0355">
<supplementary-material content-type="local-data" id="mmc1"><caption><title>Table S1. Clinical Information of the COVID-19 Convalescent Patients, Related to STAR Methods</title></caption><media xlink:href="mmc1.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc2"><caption><title>Table S2. Characteristics for the Expressed mAbs, Related to STAR Methods</title></caption><media xlink:href="mmc2.xlsx"/></supplementary-material>
<supplementary-material content-type="local-data" id="mmc3"><caption><title>Document S1. Tables S3&#x02013;S5</title></caption><media xlink:href="mmc3.pdf"/></supplementary-material>
</p></sec><ack id="ack0010"><title>Acknowledgments</title><p id="p0335">This work was made possible by the support from the <funding-source id="gs1">Beijing Advanced Innovation Center for Genomics</funding-source> (ICG) at Peking University and the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012226</institution-id><institution>Fundamental Research Funds for the Central Universities</institution></institution-wrap></funding-source> (A20ZX00846). We thank the <funding-source id="gs3">Beijing Municipal Commission of Science and Technology</funding-source> for the coordination of collaboration between institutes and financial support (Z201100005420018). We are grateful to Prof. Zhijian Chen of UT Southwestern for the stimulating discussions. We thank Prof. Yanyi Huang, Prof. Zemin Zhang, and Prof. Fuchou Tang of Peking University for their help on experimental equipment and supplies. We thank Prof. Zhanguo Li of Renmin Hospital and Prof. Chengqi Yi of Peking University for the loan of critical equipment. We thank Prof. Yingchun Wang and Dr. Weijin Huang from the Division of HIV/AIDS and Sex-transmitted Virus Vaccines, National Institutes for Food and Drug Control (NIFDC) for providing the SARS-CoV-2 pseudovirus strain and the Huh7 cell line. We thank Dr. Jie Zhang, Dr. Yutao Lin, and Dr. Wei Ren from Sino Biological Inc. for the technical assistance on mAbs expression and characterization. We thank the <funding-source id="gs4">National Center for Protein Sciences at Peking University</funding-source> in Beijing, China, for the assistance with SPR measurement. We thank the <funding-source id="gs5">National Mega projects of China for Major Infectious Diseases</funding-source> (2017ZX10304402), National Key Research and <funding-source id="gs6">Development Project of China</funding-source> (2016YFD0500304), and <funding-source id="gs7">CAMS initiative for Innovative Medicine of China</funding-source> (2016-12M-2-006) for the support on the animal model study. We thank Dr. Chuck Bailey and Prof. John Rasko from the University of Sydney and Royal Prince Alfred Hospital and Dr. Patricia Purcell from the Massachusetts Institute of Technology for critical reading and editing of the manuscript.</p><sec id="sec6"><title>Author Contributions</title><p id="p0340">Y.C. and X.S.X. conceptualized the project and designed and coordinated the experiments. X.S.X. obtained the funding for the project. R.J. and Y.F. organized the collection of convalescent patients&#x02019; blood samples. B.S. and X.G. prepared B cells and performed 10X experiments. Y.W. and L.Q. arranged sample transportation. Y.C. and C.G. performed scRNA and scVDJ library preparation. X.Z. and Y.C. optimized the antigen pull-down experiment. W.S. and X.C. analyzed the sequencing data. Y.C. selected the antibody sequences for synthesis. Y.Z. performed the pseudovirus neutralization assays. R.S.H. performed SPR assays. Z.D. and C.Q. coordinated the experiments on the authentic virus, which was developed by C.Q. Y.D., X.L., and Y.T. performed the PRNT on the authentic virus in the P3 laboratory. C.Q. designed and J.L. coordinated the animal experiment. L.B., H.Z., W.D., and Y.X. performed the animal experiment in the P3 laboratory. Q.L. performed the CPE assay in the P3 laboratory. D.S. and J.X. led the cryo-EM structure experiment. Q.Z., G.W., X.D., and N.G. collected and analyzed the structure data. Y.C. and X.S.X. wrote the manuscript with the help of all authors. L.S. arranged the figures.</p></sec><sec sec-type="COI-statement" id="sec7"><title>Declaration of Interests</title><p id="p0345">X.S.X, Y.C, W.S, and X.Z. are co-inventors on patent applications describing the neutralizing mAbs. X.Z. is the CEO of Singlomics (Beijing DanXu Pharmaceuticals, Co. Ltd.). The other authors declare no competing interests.</p></sec></ack><fn-group><fn id="app1" fn-type="supplementary-material"><p id="p0350">Supplemental Information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cell.2020.05.025" id="intref0095">https://doi.org/10.1016/j.cell.2020.05.025</ext-link>.</p></fn></fn-group></back></article>